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INTRODUCTION 
The history of specific narcotic antagonists has been both 
interesting and rewarding, beginning vi th the first report on this 
subject in 1915 by Pohl. 1 He became interested in the work of a 
colleague of his by the name of Piazza who found that allyl compounds 
were capable of stimulating respiration. Pohl hypothesized that by 
incorporating the allyl group into one of the opiates, one might 
produce a compound capable of producing a lesser degree of central 
nervous system. depression while maintaining adequate analgesia. Pohl 
found, as a result of experimentation vi th 0-allylnormorphine and 
N-ally'lnorcodeine, that the latter was relatively" inactive when given 
alone, but was capable of antagonizing the respiratory depression 
produced by morphine in dog and rabbit. 
The significance of this finding was not appreciated for over 
twenty-five years until an analogue of N-allylnorcodeine was described 
in the literature. In 1941 McCawley, Hart and Marsh2 synthesized 
what they thought was N-allylnormorphine (nalorphine N.N.R.) in order 
to study its pharmacological effect on experimental animals with the 
hope of finding a compound that would give analgesia without respiratory 
depression. However, subsequent studies indicated that this preparation 
1 Pohl, J. , Uber das N-a.l.lylcodein, einen Antagonisten des Morphine, 
Zschr. f. exper. Path. u. TherSE• 17:370, 1915. 
2 McCawley, E. L., Hart, R. E., and Marsh, D. F., The preparation of 
N-allylnormorphine, J. A.m. Chem. Soc. ~:314, 194L 
1 
was not N-allylnormorphine, but was 0-allyl-N-allylnormorphine. The actual 
synthesis of nalorphine was accomplished b.1 Weijlard and Erickson in 1942;3 
its chemical structure is shown in Figure 1. In the next two years separate 
reports appeared in the literature, one b,y Unna4 and the other b,y Hart 
and McCawley,5 which covered most of the basic pharmacology of nalorphine 
in experimental animals. These results demonstrated the ability of this 
drug to antagonize many effects of morphine. Of great significance also 
was the finding that nalorphine alone had little or no pharmacological 
activity on experimental animals in doses which were capable of preventing 
or reversing the depression produced by morphine. Since the early work 
b,y Unna and Hart and McCawley, numerous reports on experimental animals 
have appeared in the literature demonstrating the ability of nalorphine 
to antagonize most of the actions of morphine and other similar narcotics, 
whether synthetic or naturally occurring;6-l7 however, it is ineffective in 
.3 Weijlard, J. and Erickson, A. E., N-a11ylnormorphine, J. Am. Chem. Soc. 
~:869, 1942. 
4 Unna, K., Antagonistic effec't of N-all.ylnormorphine upon morphine, 
J. Pharmacol. Exptl. Therap. 1.2t27, 194.3. 
5 Hart, E. R. and McCawley, E. L., The pharmacology of N-allylnormorphine 
as compared vi th morphine, J. Pharmacol. Exptl. Therap. 82: .3.39, 1944. 
6 Winter, c. A., Orahovats, P. D., Flataker, L., Leman, E. G., and 
LelDan, J. T., Studies on the pharmacology of N-allylnormorphine, 
J. Pharmacol. Exptl. Therap. !!J:: 152, 1954. 
7 Gruber, c. M., The effect of N-allylnormorphine upon the toxicity of 
morphine, J. Pharmaeol. Exptl. Therap• !!!:404, 1954. 
8 Orahovats, P. D., Winter, c. A., and Lehman, E. G., The effect of 
N-allylnormorphine upon the development of tolerance to morphine in 
the albino rat, J. Pharmacol. Exptl. Therap. 109:41.3, 195.3. 
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FIGURE 1: Chemical structure of the specific antagonists and 
the narcotics that they resemble, plus the structure of daptazole 
( 1) Morphinan type: 
(a) Narcotic: 
HO 
(b) Antagonist: 
. y-cH2-CH-cH2 
CH2 
levorphan (levo-dromoran) j.. -3-hydroxy-N..m.ethylmorphinan 
levallorphan J. -3-hydroxy-N-allylmorphinan 
(2) Morphine type: 
(a) Narcotic: 
morphine 
(c) Antagonist: 
y-cH2-CaCH 
CH2 
n propa,llorphan (Ro-1 .. 7780) 
~-3-hydroxy-N-propargylmorphinan 
(3) Daptazole: 
2,4-diamino-5-phenylthiazole 
NH2, N 
>-4.:..1 JLNH s 2 
(b) Antagonist: 
f-CH2.CH=-CH2 
CH2 
nalorphine 
N-allylnormorphine 
3 
9 Huggins, R. A., Glass, W. G., and Bryan, A. R., Protective action of 
N-al.17llloraorphine agai.Dst respiratoey depression produced by SOBle 
compounds related to aorpbine, Proc. Soc. Exptl.. Biol. Med. 1.2:.5lt0, 19.50. 
10 Bauer, R. o., Effects of opiate-nalorphine mixture on respiratoey 
perfonunce in anesthetized dogs exposed to lJ1porla, Fed. Proc. llu 317, 
u~ -
11 Bodman, R. L, The depression of respiration by" the opiates and its 
antagoni• by" nalorphine, Proc. Roz. Soc. Med. !2:923, 19.53. 
12 Green, A. F. and Ward, N. B., The action of analgesics and nalorphine 
on the cough renex, Brit. J. Pbarm. lQ.:419, 195..5. 
13 Gruber, c. M. and Gruber, c. M., Jr., N-allylnoraorphine as an 
antagonist to the intestinal spasa produced b;y the addicting analgesics, 
J. Pbarm. E!ptl. Therap. 109:1.57, 19.53. 
14 Irwin, s. and Seevers, M. H., ComparatiYe study' of regular and N-ally'1-
nol"'llorphine induced vi thdrawal in aonkeys addicted to morphine, 6-eetby1-
dih1droaorphine, Dromoran, methadone and ketobemidone, J. Pharm. Exptl.. 
Therap• ~~ 391, 19.52. 
1.5 Radoff, L. M. and Huggins, s. E., Protective action of lf-al.l7lllor-
morphine against Demero1, Proc. Soc. E!ptl.. Biol. Med. :z!t879, 19.51. 
16 Weiss, B., The effects of nrious aorpbine-1f-all71•normorpbine ratios 
on beharlor, Arch. int. pbanlaco<bn. 10$:381, 1956. 
17 Schneider, H. and Blackmore, E. L, The effect of nalorphine on the 
antidiuretic action of morphine in rats and aan, Br1 t. J. Pharm. 
10, 45, 19.5.5. 
-
neutralising the depression produced b;y barbiturates, ether, or cyclo-
propane. 18 These :findings were rerlewed by Lasagna in 19.54, 19 and aore 
18 Eckenhoff, J. E., Elder, J. D., and King, B. D., N-allylnoraorphine 
in the treatlllent of 110rphine or d•erol narcosis, Am. J. Med. Sci. 
223:191, 1952. 
-
19 Lasagna, I., Nalorphine (N-al17lllormorphine) : Practical and theoretical 
considerations, A.M.A. Arch. Int. Med. _2!:.532, 1954. 
4 
recently b.Y Woods. 20 It is interesting to note that the convulsions 
produced in rats, mice or rabbits b.Y morphine or meperidine were not 
abolished by nalorphine.21,22 
Although there was a definite need for an antagonist to narcotics 
at the clinical level, it was not until 1952 that nalorphine was tested 
and found to be usefu1. 18 Other clinical reports have been made over the 
last four or five years demonstrating the anti-narcotic effect of this 
drug.23-39 
20 Woods, I. A. , The pharmacology of Nalorphine (N-allylnormorphine) , 
Pharm. Rev. !!,:175, 1956. 
21 Koppanyi, T. and Karczmar, A. G., Nature of antagonism between N-allyl-
normorphine (Nalline) and morphine, Fed. Proc. g: 331, 1953. 
22 Winter, C. A. and Flataker, I., Effect of N-allylnormorphine upon 
massive doses of narcotic drugs, Proc. Soc. Exptl. Biol. Med. 93:158, 
1956. 
23 Adriani, J. and Kerr, M., Clinical experiences in the use of N-allyl• 
normorphine (Nalline) as an antagonist to morphine and other narcotics 
in surgical patients, Surgery ~:731, 1953. 
24 Beal, J. M. and Schapiro, H., Effect of N-allylnormorphine on gastro-
intestinal motility, Surgery _ll:65, 1953. 
25 Bornstein, M., Yorburg, I., and Johnston, B., N-allylnormorphine in 
treatment of methorphinan (Dromoran) hydrobromide poisoning, J. Am. 
Med. Ass. 151:908, 1953. 
26 Cappe, B. E., Himel, s. I., and Grossman, F., The use of a mixture of 
morphine and N-allylnormorphine as an analgesic, Am. J. Obstet. G;ynec. 
§2: 1231, 1953. 
27 Chase, H. F. and Boyd, R. s., N-all7lnormorphine in treatment of 
dihydromorphinone and methorphinan overdosage, J. Am. Med. Ass. 
!2Q.:ll03, 1952. 
5 
28 Cullen, s. c. and Santos, c. c. , Analgesia for chronic pain without 
respiratory depression, A.M.A. .lrcb. Sllrg. ,22:410, 19.54. 
29 Domino, E. F. and Pelikan, E. w., lall1ne (nalorphine) antagoni• to 
racemorphan (Dromoran) intoxication, J. Am. Med. Ass. illt 26, 1953. 
ll Eckenloff, J. E., Hoffman, G. L. , Jr. , and Funderburg, L. w. , 1-allyl-
normorphine: an antagonist to neonatal uarcosis produced by' sedation 
of the parturient, Am. J. Obstet. GlDec• 22t 1269, 1953. 
ll Is Fraser, H. F., Wikler, A., Eisemun, A. J. 1 and bell, H., Use of 
l-all.7l.norm.orphine in treat:aemt of aetbadone poisoning in man, J. Am. 
Med. Ass. 148:1205, 1952. 
32 Gabriels, A. G., Jr. and Fitsgerald, w. J., Morphine and Balline in 
obstetric analgesia, observations in l.SO patients, N.Y. State J. Med. 
,22:3113, 1955. 
33 Keats, A. s. Uld Mithoefer, J. c., lature of antagoniSBl of nalorphine 
to respiratory depression induced by' morphine in aan, Fed. Proc. llu 
356, 1955. -
34 Landaeaser 1 c. M. 1 Cobb, s., and ConTerse, J. G. 1 Effects of 1-allyl-
normorpbine upon the respiratory depression due to morphine in 
anesthetized man with studies on the respiratory response to carbon 
dioxide, AnesthesioloR !!: 535, 1953. 
35 Marx, F. J. and IA:>ve, J. 1 Effectiveness of 1-allyl.noraorphine in the 
management of acute morphine poisoning, Ann. Int. Ked. J2t635, 1953. 
36 Paterson, s. J. and Prescott, F. 1 Nalorphine in the prevention of 
neonatal aspb1xia due to maternal sedation w1 th pethidine, Lancet 
!t490, 1954. 
31 Salomon, A. 1 Marcus, P. s., Herschus, J. A. 1 and Segal, M. s., 
N-allylnormorpbine (lalline) action on narcotized and non-narcotized 
subjects, b. J. Hed. 11:214, 1954. 
38 Van Liere, E. J. and Northup, D. 1 Effect of nalorphine on gastric 
emptying in un, Proc. Soc. Exptl. Biol. Med. _2!:619, 1956. 
39 Wilder, A., Fraser, H. F. 1 and Isbell, H. 1 N-allylnoraorpbinet effects 
of single doses and precipitation of acute "abstinence syndromes" 
during addiction to morphine, methadone or heroin in JI8D (post addicts) , 
J. Pbarm. E.xptl. Therap. 109:8, 1953. 
6 
The highly specific action of nalorphine in opposing the action of 
narcotics lead to the synthesis and evaluation of other potential 
narcotic antagonists which were N-~1 derivatives of morphine and 
synthetic analgesics. 40-43 Of these newer drugs, two are of particular 
interest, ~-3-hydrox,--N-all.yl morphinan (levallorphan} tartrate and 
1-3-hydrox,--N-propargyl morphinan (propallorphan, Ro-1-7780*} tartrate 
which are shom in Figure 1, page ,3. 
Levallorphan was studied for the first time in the experimental 
animal b7 Fromhers and Pell.aont in 19S2. 44 These authors demonstrated 
the ability of this drug to neutralise the respiratory depression pro-
duced by' morphine and levorpban (levo-dromoran}. Costa and Bonnycastle4S 
in further studies showed that levallorphan was capable of antagonizing 
the respiratory depressant and analgesic action of aetbadone, meperidine, 
morphine, alphaprodine, and levorpban in rats. Benson et al. 46 showed 
* Ro-1-7780 does not as yet have a name; however, in this paper it vlll 
be called propallorpban. 
40 Clark, R. L., Pessolano, A. A., Weijlard, J. t and Pfister, L, N-substi-
tuted epoJcylllorphinans, J. A.m. Ch-. Soc. 12:4963, 1953. 
41 Green, A. F., Ruffell, G. L, and Walton, E., Morphine derivatives 
with antiana.lgesic action, J. Pbamacz and Pbanlacol. ( Lond.} 6: 390, 
19.54. 
42 Schnider, o. and Hellerbach, J., Synthesis of morphinans, Helv. Chim. 
~ Jl: 1437 J 1950. 
43 McCoubrey, A. , J.ntagoniSJil of analgesia by p-eyclo-hexylox,--"-PheDTl-
etbylal:cyl.aaine and some obse"ations on ~eralgesia, Brit. J. 
Pharllacol. ,2:288, 19.$b. 
44 Fromherz, L and Pel.lmont, B., Morphinantagonisten, E;xperientia !: 394, 
19S2. 
7 
45 Costa, P. J. and BoDnJ'Castle, D. D. 1 The effect of levallorphan 
tartrate, nalorphine }V'drochloride and WIN 7681 (l-all.yl-4-phen71-
4-carbethoxy-piperidine) on respiratory depression and analgesia 
induced by some active analgetics, J. Pharaacol. Exptl. Therap• 
113:310, 1955. 
46 Benson, w. M., O'Gara, E., and VanWinkle, S., Respiratory and analgesic 
antagonisa of Dromoran (racem.orphan) by' l-3-eydroxy-N-al.l71 morphinan, 
J. Pbarllacol. E!:ptl. Therap. ~:373, 1952. 
in rabbits that narcotic-induced depression is reversed b.r levallorp~ 
Still other reports appeared in the literature corroborating and apanding 
the initial finding with levallorphan in experiaental animals. 47-Sl 
Finally in 1953, Hamil ton and Cullen 52 published the first clinical 
report on this drug which substantiated the results found in experimental 
47 Miller, J. w., Gil.toil, T. M., Shideman, F. E., The effects of levallor-
phan tartrate (levo-3-eydroxy-N-ally'lmorphin tartrate) on the respira-
tion of rabbits given morphine, J. Pbaraacol. Exptl. Therap. llSt350, 
1955. 
48 Iia, G. L W. , Keasling, H. H. , and Gross, E. G. , Silaul taneous respira-
tory lllin11te voluae and tooth pulp threshold changes following cln-onic 
adainistration or levorphan and levorpban-levallorphan mixtures in 
rabbits, J. Pbarmacol. E!ptl. Therap. ,Y!:l93, 1956. 
49 Gruber, c. M. , Effect of levallorphan tartrate upon torlci ty o.t 
morphine, Proc. Soc. Exptl. Biol. Hed. ~:1.89, 1955. 
50 lei th, E. F. , Deboer, B., and Mukolllela, A. E. A nalorphine analogue 
as an antagonist to blood changes induced b7 narcotic achldnistration, 
Fed. Proc. ,!!:357, 1955. 
51 Gray, G. w., Effects of certain analgesic and analgesic-antagonist 
drugs on intestinal motility, J. Pharaacol. Exptl. Therap• 116:24, 
1956. 
52 Hamil ton, W. L and Cullen, S. C. , Effect of levallorphan tartrate upon 
opiate induced respiratory depression, Anesthesiolosz ]!.: 550, 195). 
8 
animals. The results in both aniJM] and man indicate levallorphan is 
a aore potent narcotic antagonist than nalorphine. 45-53 
While levallorphan bas been inTestigated to some extent, propallorphan 
has hardly been touched. Malorny-.54 compared it with levallorphan and 
nalorphine in regard to their ability to antagonize the increased motor 
activity produced by' morphine or levorpban in mice. This study" indicated 
levallorphan was the most potent of the three, with propallorpban a close 
second and nalorphine a poor third. The only other report in the literature 
on propallorphan was made by Pittinger et al. .5.5 These authors demonstrated 
the ability of this drug to potentiate the byperglycemic response of 
either morphine or levorphan in fasting mongrel dogs. In contrast to this, 
levallorphan and nalorphine briefly suppressed the QJ.perglycemic response 
produced by both narcotics when given contemporaneously. 
Thus far we have discussed drugs which specifical].y antagonize the 
narcotic analgesics. In a series of studies by Shaw and Bentley, 56,51' 58 
53 Eckenhott, J. E. and Funderburg, L. W., Observations on the use of the 
opiate antagonists nalorphine and levallorphan, Am. J. Med. Sci. ~: 546, 
1954. 
54 Malorny, G., Zur Wirkungsweise apezifischer Morphinantagonisten. L Die 
Beeinflussung der Zentralerregenden Wirkung TOD Morphin-Vernandten und 
N-aethylmorphinan Derivaten bei der Maus, Arz. Forsch. _2:252, 19.55. 
55 Pittinger, c. B., Gross, E. G., and Richardson, o. M., The effect of 
nalorphine, levallorphan and analogues of levallorphan upon the byper-
gl.ycemic response of dogs to lewrpban. J. Pharaacol. Expt. Therap. 
lllu439, 1955. 
S6 Shaw, F. B. and Bentlq, G. A., Soae aspects of the pharllacology of 
morphine, with special reference to its antagonisa by' $-amino-acridine 
and other chemicall7 related compounds, Med. J • .lust. £1868, 1949. 
9 
57 Shaw, F. B. and Bentle;y, G. A.., Morphine antagoniSJil, Mature 169:712, 
1952. 
58 Shaw, F. B. and Bentley, G. A., Morphine antagonia, .Aust. J. Exptl. 
Biol. Ked. Sci. Jit 143, 1955. 
these authors found aminoacridine and related compounds were capable or 
antagonizing morphine-induced respirato17 and circulato17 depression in 
uperimental animals. These compolUlds are not specific antagonists of 
opiates and show a high incidence of side effects; namely, central nervous 
syste stilllulation. However, one compound studied in this group showed 
the greatest promise in experimental animals as a possible antagonist not 
onl.7 to morphine, but to barbiturates as well. 59-64 This compound, 
2,4 diamino-.$-phenylthiazole (daptazole) h1drobr011ide, was first synthesized 
in 19So. 65 Its chemical structure is presented in Figure 1, page 3-
59 Shaw, F. H. and Shulman, .A., Morphine antagonisa, Nature 17$:388, 1955. 
60 Shaw, F. B., Simon, S. E., Cas~1 N., and Shullllan, .A., Barbiturate 
antagonia, Nature 174:1&02, 19.54-
61 Harris, T. A. B., A barbiturate antagonist, Lancet != 181, 19$$. 
62 Shaw, F. H. and Shul.Jilan, .A., Treat&ent of intractable pain with large 
doses of morphine and diamino-phenyl thiazole, Brit. Med. J. !: 1367, 
1955. 
63 Shulman, .A., Shaw, F. B., and Cass, N., A new treatment of barbiturate 
intoxication, Brit. Ked. J. !:1238, 1955. 
~ McKeogh, J. and Shaw, F. B., Further experience with Wphenazole and 
morphine in intractable pain, Brit. Med. J. !:142, 19$6. 
65 Davies, w., Macloren, J. A., and Wilkinson, I. R., Synthesis and 
properties of 2,4-diaminothiazoles, J. Cham. Soc. 3941, 19$0. 
10 
According to the authors, daptazole was found in man to be capable of 
neutralizing morphine depression, and had the additional advantage of 
not altering the analgesia produced by the narcotic. This action differs 
from the specific narcotic antagonists which in high enough doses can 
prevent or abolish both the respiratory depression and the analgesia 
produced by the opiates,66,67,68 
MOst drugs studied for their possible antagonism of narcotics were 
first tested against morphine and then against other naturally occurring 
and synthetically prepared analgesics. Three narcotics were used in the 
present study, morphine, meperidine and alphaprodine, which warrant some 
conment at this point. MOrphine is obtained from the poppy plant which 
is indigenous to Asia Minor, Opium (Greek name for juice), which contains 
the active alkaloids including morphine, is obtained from the juice of 
the poppy capsules, Opium preparations have been used for centuries 
as the crude extract, Finally in 1806 Sertiirner isolated morphine from 
the crude extract and described it, 69 and it is from this source that we 
66 Orahovats, P. D., Winter, C. A. , and Lehman, E. G. , Pharmacological 
studies of mixtures of narcotics and N-allylnormorphine, J. Pharmacol, 
Exptl, Therap. m:246, 1954. 
67 Smith, C, C., Lehman, E, G,, and GUfillan, J, L,, Antagonistic action 
of N-allyl-normorphine upon the analgetic and toxic effects of morphine, 
methadone derivatives and isonipecaine, Fed, Proc, .!Q:JJ5, 1951. 
68 Houde, R. w. and Wallensten, s. L., Clinical studies of morphine-
nalorphine combinations, Fed, Proc. ll:440, 1956. 
69 Sertlirner, F. w., Darstellung der reinen MOhnsaiire (opiumsaure) nebst 
einer chemischen Untersuchung des Opiums mit vor.uglicher Hinsicht auf 
ein darin neu entdeckten Stoff und die dahin gehorigen Bemerkungen, 
J.d. Pharm. f. Aertte. Apoth, u, Chem., 1:!J:.:47, 1806. 
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still prepare morphine and dispense it generally as the sulfate salt. 
Although morphine has recently been prepared &)'llthetically, 7° the cost 
of this method of preparation is prohibitive. O:f all the analgesics 
available to the medical profession, it is generally conceded morphine 
is the most useful. 
Many other analgesics have been isolated from their natural sources, 
and still others have been prepared S)'llthetically. The other two anal-
gesics of interest here are meperidine, which was first synthesized b,y 
Eisleb and Schaumann in 1939, 7l and alphaprodine, which was prepared by 
Ziering and Lee in 1947.72 The latter analgesic is more potent than 
meperidine and less potent than morphine. 13,74 
70 Gates, M. and Tschudi, The synthesis of morphine, J. Am. Chem. Soc. 
74:1109, 1952. 
71 Eisleb, o. and Schaumann, o., Dolantin, ein neuartiges Spasmolytikum 
und Analgetikum ( chemisches und pharmakologisches), Deutsch. med. 
Wochenschr. ~:967, 1939. 
72 Ziering, A. and Lee, J., Piperidine derivatives, v. 1,3-dialkyl-4-
aryl-4-acyl-oxypiperidine, J. Org. Chern. ,!g,:911, 1947. 
13 Foster, R. H. K. and Carman, A. J., Studies in Analgesia: piperidine 
derivatives with morphine-like activity, J. Pharmacol. Exptl. Thera£• 
g: 195, 1947. 
74 Keasling, H. H. and Gross, E. G., The effect of analgesics on radiant 
heat thresholds in man, Anesthesiology 17:809, 1956. 
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PURPOSE 
One of the major undesirable actions of narcotics is the marked 
respirator.y depression which accompanies their analgesic effect. 
Attempts are currently' being aade by investigators to prevent this 
depression without affecting the analgesia through the conjoint use 
of narcotics and antagonista.44,4S,46,4S,b6,o7,06 
It was the purpose of this study': 
1. to evaluate quantitatively the antagonism of propallorphan against 
narcotics in the dog. llaphasis vas placed on the changes in general 
responsiveness (objective signs of stiaulation or depression) and 
respiration which are produced by these drugs 
2. to evaluate quanti tativel7 the antagoniSlll of propallorpban, levallor-
phan and daptazole against narcotics in man with special reference to 
changes in general responsiveness, respiration and analgesia. Attempts 
were made to find dosage ratios of antagonist to narcotic which would 
mjni•ise the respiratory depression while allowing the maintenance of 
adequate analgesia. 
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METHODS 
L Animal Studies: 
Propallorphan tartrate* (Ro-1-7780) was tested in conscious dogs 
and in dogs anesthetized with sodium pentobarbital,* 25 to 30 mg./kg. 
Male or female dogs weighing 8 to 12 kg. were chosen and all drug 
injections were made intravenously. Alpha.prodine hydrochloride* (2 ... 
10 mg./kg.) was administered in control studies on six conscious dogs, 
and in later experiments in the same animals propallorphan, o. 25 or 
o. 5 mg. /kg., was given at the time of maximum apparent depression 
following administration of alphaprodine. Respiration, pulse rate and 
general responsiveness were observed. The latter was graded on a scale of 
1 to a, 6 being the condition of the untreated dog. Any value below 6 
indicated a depressed state, and any value above this stimulation. Two 
dogs received morphine sulfate,* 1. 5 or .3. 0 mg. /kg., in similar studies. 
Experiments were next carried out to determine the effect of 
propallorphan in established alphaprodine depression in anesthetized 
dogs. The nine animals used in this phase of the work were given pen to-
barbital and an endotracheal tube inserted. Expired gas volumes were 
measured using a wet test gas meter, and the expired air was collected 
at appropriate time intervals to be analyzed later for oxygen and carbon 
* Generic names without salt designations will be used throughout the 
rest of the paper for convenience. All dosages are given in terms 
of the salt. 
dioxide content b,y the method of Scholander75 using a micromet gas 
analyzer. Femoral arterial and superior vena cava blood samples 
were also collected at appropriate times to be analyzed for oxygen 
and carbon dioxide content by the method of Van Slyke and Neill76 
using a manometric gas apparatus. Respiration and pulse rate were 
counted directly; oxygen consumption was calculated from the expired 
gases and ventilation. Fifteen to 20 minutes after tracheal intubation 
in each animal, alphaprodine (5 or 8 mg./kg.) was injected. Artificial 
respiration was required for a period of 1 to 5 minutes in all animals 
in order to prevent death. On the resumption of spontaneous respiration, 
observations were made (first set of measurements). Approximately 5 
minutes later propallorphan (0.25 or 0.35 mg./kg.) was injected and the 
measurements (second set) repeated within 3 to 1 minutes. In control 
experiments, which were carried out 1 to 10 days before or after the test 
experiments on these dogs, measurements were made under pentobarbital alone 
at two different times which corresponded to the first and second sets of 
measurements mentioned in the test experiments. In four dogs, propall· 
orphan (0.25 or 0.35 mg./kg.) was injected before the second set of 
measurements was made in the control study. 
A similar experimental design was used in eight anesthetized dogs 
75 Scholander, P. F., Analyzer for accurate estimation of respiratory gases 
in one-half cubic centj.meter samples, J. Biol. Chem. 167:235, 1947. 
76 VanSlyke, D. D. and Neill, J. M., The determination of gases in blood 
and other solutions by vacuum extraction and manometric measurements. 
VII. Combined determination of oxygen and carbon dioxide in blood, 
J. Biol. Chem. 61: 561, 1924. 
15 
that received alpbaprodine alone (4 or 5 mg. /q.) in control experiments, 
while this dose of narcotic was given simultaneously with 1/75 or 1/lOOth 
the amount of propallorphan in test studies. Respiratory volume and rate 
were followed before and for at least 45 minutes after drug injections 
were made in both the control and the test experiments. Femoral arterial 
blood was draa 5 to 8 and )) to 40 minutes following administration of 
the narcotic or of the narcotic-antagonist coabination for determination 
of oxygen content. 
On seven anesthetized dogs continuous recordings were started for 
respiratory voluae and rate and heart rate. Following a 10 minute control 
period, morphine was injected in a single dose of 2 mg./kg. The measure-
ments were then continued until the animals recovered from the effect 
of the opiate. In test experiments on the sam.e animals at a different 
time, the same procedure was followed as above, only in this case 
propallorphan was injected after the respiratory depression from morphine 
had developed. The antagonist was injected in doses of o.oa mg./kg. in 
six experiments, o. 2 mg. /kg. in another six, and 1 mg./kg. in one experi-
ment. 
2. Human Studies: 
(a) Uphaprodine series: 
Suitable patients were selected following surgery, experiments 
being carried out in the usual postoperative environment of the recovery 
room at Boston City Hospital. Ventilation, blood pressure, pulse and 
general responsiveness of the patients were observed at five minute 
intervals until they had been stable for three successive readings. 
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.A.lpbaprodine, pby'siological saline, propallorphan1 levallorphan tartrate,* 
or a combination of alphaprodine with propallorphan or levallorphan was 
then injected slowly' by vein. The Tentilation, blood pressure, pulse and 
responsiyeness were recorded at 2, 5, 101 15, 20, 25 and 30 minutes, in 
som.e cases later observations were also made at longer intervals. J.D.7 
unusual manifestations which occurred during the experiments were also 
noted. 
One-hundred and sevent;y patients were initially' chosen for the stud;r, 
but twent,r-seven of these were rejected before completion of observations 
either because they manifested annoyance vi th the procedure or because 
consistent control values of Jlinute Yentilation could not be obtained. 
J.ll the patients in the study had received spinal or local anesthesia, 
and thirteen bad been given light general anesthesia in addition. lo one 
who had been under deep or prolonged general anesthesia was used. After 
the first twenty or thirty patients, age or general condition was not 
considered, except that indiTi.duals in poor cardiovascular status, mani-
fested by a systolic blood pressure of less than 90 -. Hg or a pulse rate 
above 120, were not used. J.ge range was 12 to 81 years, ayerage 48 ;rears; 
the weight varied from .36 to 109 kg. 1 aTerage 69 kg. All patients had 
been medicated preoperativel;r according to the orders of an anesthetist 
who had no knowledge that they would be used in this stud;r. 
Blood pressure was taken by auscultation using an aneroid spb7gmo-
manOJReter, and radial pulse was counted. either just before or just after 
* See page 14. 
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the observations on respiration. Inspiratory volume was measured !or 
one minute of every five using a Bennett respiratory ventilation meter, 
and respiratory rate was counted simultaneously. Four or five sets of 
observations were frequentlY required before three successive consistent 
values (varying by not more than 10%), which were taken to be "normal" 
ventilation for this patient, were obtained. The drug, drug combination, 
or indifferent solution (physiological saline) was then injected, usuallY 
through infusion tubing, but occasionally by direct venipuncture. 
Minute ventilation, respiratory rate and tidal volume were calcu-
lated as percent of the "normal" value for each patient, ttnormal" being 
considered 100 percent. Responsiveness was graded on a scale of ! to !u 
_!, meaning aroused with difficulty; b aroused with ease; _2, no change 
in responsiveness after the medication; and 1!, showing signs of central 
nervous system stimulation. 
The drugs and combinations, and the number of patients receiving 
each, are indicated in Table 1. Alphaprodine was administered at o. 375 
or 0.75 mg./kg., propallorphan at 0.0375 or o.o75 mg./kg., levallorphan 
at 0.075 mg./kg., and saline solution at a dose of 1.5 or 2.0 ml.; these 
were the control medications. Combinations of propallorphan or levallor-
phan with alphaprodine (0.315 or 0.75 mg./kg.) were given in ratios of the 
antagonist to analgesic of 1: 100* to 1: 5* in order to determine the combined 
effects. The various drugs and combinations were given in random order, 
except at the beginning when the useful range of antagonist dosage was not 
* All ratios are expressed as antagonist to narcotic throughout this paper. 
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T.ABLE ls Numbers of Patients Receiving Various Drugs and 
Drug Combinations in the !lpbaprodine Series 
Alphaprodine Ratio: Ro-1-7780 to Number of I Alpbaprodine Ratiosr levallorphan Humber of mg/kg alpbaprodine, or patients llgfkg to alphaprodine, or patients dose Ro-1-7780 dose levallorphan 
or saline 
o.37S 0 9 o.37S lsSO 6 
l:SO 6 ls2S 6 
1:2S 6 o.7S 1:100 6 
ltlO 6 lr5o 6 
l:S 6 1:37. s 6 
o.7S 0 9 1:2S 6 
1:100 6 1:10 6 
ltSO 6 laS 6 
1:2S 6 I 1.0 1:2S 3 1:10 6 l.S 1:2S 3 
2.0 lr2S 3 
0 Ro-l-7780:0.037S 8 l 0 levallorphan a 6 ~ o.o7S mg/kg o.o7S mgjkg 
0 p~siological 6 
saline, 1. S or 
2.0 ml 
~ 
kno11ll, and at the end where each group was tilled out to a certain number 
ot patients. The Ve%"7 high doses ot alphaprodine (1.0, 1.5 and 2.0 ag./ 
kg.) were also added at the end. 
.At the begimrl.ng ot the experiment patients were told, "We are going 
to study' your breathing tor a while." If they asked questions, they were 
told, "We are measuring the breathing of a lot of patients to see how it 
goes after their operation." When a satisfactory normal value of minute 
ventilation had been obtained, the drug or combination was administered 
by a different person from the one u.ld.ng the observations. The patients 
had no real knowledge of the nature or purpose of the work'. 
After a maber ot experi.Jilents bad been carried out, it was found 
that respiration returned to essential.l7 noraal values within less than 
a halt hour after drug admi n1 stration. Once this had been established, 
observations were continued tor only )) lllinutes after the medication had 
been given. Following this period, patients were kept under close obser-
vation in the recovery room for an additional )) to 60 minutes, measure-
ments being made at 15 llinute intervals in some cases. No remarkable 
changes were seen during this post-experiaental interval. 
{b) M!feridine series: 
With the exception of the drug combinations tested and the length 
of ti.Jile of the observations made after drug treataent, the same experi-
mental design was used here as was used in the alphaprodine series of 
experiments. 
Excluding the patients receiving levallorphan or physiological saline, 
a total of eighty postoperative patients were finally- selected for this 
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study. All patients in this study had received spinal or local anesthesia, 
and nine bad been given light general anesthesia also. Greater care was 
used here than in alphaprodine e2periments in the selection of patients, 
particularly those who received meperidine hydrochloride* alone due to the 
danger of cardiovascular collapse with this narcotic.77,78,79 The age 
range was 19 to 78 years, average 48 years; and the weight varied from 40 
to 125 kg., average 68 kg. All patients bad been medicated preoperatively 
as described earlier. 
Meperidine, daptazole, or a combination of meperidine with daptaao1e 
or levallorphan was then prepared for injection. The measurements mentioned 
in the alphaprodine experiments were recorded at 5 minute intervals until 
a steady state was established, and then an injection was made and measure-
ments recorded at 5, 10, 20, )), lao, SO, and f:O minutes after drug treat-
ment; in some cases later observations were also ~~&de at 15 minute intervals 
for the next )) to 45 minutes. 
The drugs and combinations, and the nUIIber of patients receiving each 
are indicated in Table 2. Levallorphan and physiological saline were 
* See page 14. 
77 Batterman, R. c., Clinical effectiveness and safety of a new synthetic 
analgesic drug Demerol, Arch. Int. Med. 1!: .345, 194.3-
76 King, B. D., Elder, J. D., and Dripps, R. D., The effect of the intra-
venous administration of meperidine upon the circulation of man and 
upon the circulatory response to tilt, Surg. Gynec. Obst. 2!!:591, 1952. 
79 Harvey, P. w., Berkman, F., and Leonard, J., Caution against the use 
of meperidine hydrochloride (isonipecai.De, demero1) in patients with 
heart disease, particularly auricular nutter, AIL Heart J. !2_:758, 
1955. 
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Meperidine 
mg/kg 
1.5 
0 
0 
TABLE 2: Numbers of Patients Receiving Various Drugs and Drug 
Combinations in the Meperidine Series 
Ratio of levallorphan to Number of "eperidine Ratio of daptazole to 
meperidine or dose of patients mg/kg meperidine or dose of 
levallorphan daptazole 
0 10 1.5 1:15 
1:120 10 I 1:8 
l:l() 10 I 1:4 
l:J) 10 I lt2 
l:lS 10 
levallorphan 
o.o75 mg/kg 
6 
0 daptazole 
· 0. S or 0.8 mg/kg 
pbJsiologieal saline 6 
1. 5 or 2.0 m1 
Number of 
patients 
6 
6 
6 
6 
6 
N 
N 
included in this table for completeness. Meperidine was injected at 
1..5 mg./kg. and daptazole at 0 • .5 or 0.8 mg./kg. alone. Combinations of 
meperidine at 1. .5 mg./kg. plus levallorphan were given in ratios ot 1:120 
to 1:1.5 and with daptazole at ratios or 1:1.5 to 1:2. In preliminary 
experiments daptazole (o • .5 mg./kg.) was tested in combination with 
meperidine at doses of the latter of 1.0, 1. .5 and 2.0 mg./kg. Onl7 two 
patients were used at each of these three combinations to ascertain 
whether this dose of daptazole is at least a sate dose to give a patient 
and to see it it might prevent the respiratoey depression caused by 
meperidine. The lower dose ot the narcotic (1.0 mg. /kg.) was tested 
first vi th daptazole, then the 1. .5 mg. /kg. 1 and last the 2.0 mg. /kg. 
dose; before the ratios listed in Table 2 were studied in more patients. 
(c) Morphine series: 
The experimental design used in the other human studies was also 
followed here. A total of thirty-three postoperative patients who had 
received either local or spinal anesthesia were chosen for this study. 
Fifteen of these received morphine at a dose of 0.2 mg./kg., six at 
0.1.5 mg. /kg., twelve morphine (o. 2 mg. /kg.) plus levallorphan at a ratio 
ot either 1:10 or 1:.5. (Six patients at each ratio.) The age range was 
17 to 72 years, average 47 years; and the weight varied from 50 to 
86 kg. , average 67 kg. 
The measurements were made in the same manner and at the same time 
intervals as was done in the meperidine series of experiments, except 
that the results were recorded for 2 hours rather than for only one 
hour after drug injections. 
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RESULTS 
L Animal Studies: 
This phase of the study demonstrated that propallorphan was an 
effective antagonist to the depression produced by either morphine or 
alphaprodine in conscious or anesthetized dogs. The efficacy of 
propallorphan in combating this depression was first investigated in 
six conscious animals. While respiratory rate, tidal volume and pulse 
rate were variable and unpredictable, general responsiveness was affected 
in a consistent way following alphaprodine and after propallorphan. The 
responsiveness is summarized in Figure 2. On the extreme left, general 
responsiveness is graded on a scale of 1 to 8. Reading from left to right, 
the first column is the average condition of the untreated animals; the 
second column is the responsiveness 20 minutes after alphaprodine (2 to 
10 mg./kg.) in control experiments; the third column is the average results 
in the test experiments 20 minutes after alphaprodine; and the fourth and 
fifth columns show the effect 2 and 30 minutes after a single injection 
of propallorphan (0.25 or o.5 mg./kg.) which was given at the time of 
maximum depression produced b.r the analgesic. The reduction in general 
responsiveness after alphaprodine, which is shown in Figure 1, page 3, 
was a consistent finding seen in all dogs; and propallorphan was effective 
in every animal as well. The two animals that received morphine responded 
similarly to the antagonis~ 
The results in the nine anesthetized dogs, showing the effect of 
propallorphan (o. 25 or o. 35 mg. /kg.) in established alphaprodine (5 or 
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FIGURE 2 
Average change in general responsiveness following alphaprodine and 
propallorphan (Ro-l-778o) on six dogs 
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8 mg./kg.) depression, are presented in Tables 3A and 3B, and the statisti-
cal* comparison of the results in Table 4. The depression of ventilation, 
arterial and venous oxygen contents produced by' alphaprodine alone were 
significantly different from the control values (Table 4, CN cf. N); and 
the antagonist given after the narcotic caused a significant (N cf. A) 
improvement in ventilation, respiratory rate, oxygen consumption (Vo2), 
arterial oxygen and carbon dioxide content, venous oxygen content, and 
expired oxygen and carbon dioxide. The antagonist caused a significant 
improvement in minute ventilation, respiratory rate, arterial oxygen and 
carbon dioxide content, venous carbon dioxide content, and expired oxygen 
and carbon dioxide which exceeded the control values (CN cf. A). Compari-
sons made between the various controls (CN cf. CA and CN cf. CP) did not 
show significant changes. 
On the basis of these experiments a somewhat lower dose of alpha-
prodine (4 or 5 mg./kg.) was chosen as suitable in the subsequent animal 
work. 
Figure 3, page .30, shows the mean results from studies of the 
combined administration of propallorphan and alphaprodine in dogs. 
Preliminary experiments indicated that the antagonist should be given 
in a dose of about l/75th to 1/lOOth the narcotic in order to prevent 
respiratory depression. The administration of alphaprod.ine by itself 
* This and subsequent 11p11 values were calculated by Student's 11 t" test. 
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TJ.BLE .3A: The Influence of Propallorpban Foll~g 
J.lphaprodine in the Dog Under Pentobarbital 
:j3lood Gases 
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EJcpired 
Dog Code Venti- Resp. Vo~ Arterial Venous Heart Air No. No.* lation Rate ml Rate 
L/min min P2 Vols % co2 Vola % o2 Vols % C02 Vols % 02 % 
1 2 3 4 5 6 1 8 9 
2# 
N 1.54 16 19 '16.2 40.0 5.5 45.9 140 16.2 
~~a) 1.85 21 76 18.6 42.8 11.5 46.6 100 17.1 4.80 ~ 84 21.3 36.0 10.1 42.6 1~ 19.2 
CA NOT DONE, DOG m POOR SHAPE 
3# 
N 2.00 16 56 18.3 5o.4 11.4 56.6 125 18.3 
~Ya) 2.95 19 125 16.4 68.9 10.6 74.0 105 17.7 2. 72 16 48 20.1 44.6 12.4 54.0 120 19.1 
CA(a) 2.67 19 81 16.2 68.9 12.0 76.6 1~ 17.9 
4# 
N 0.94 7 44 14.4 41.5 6.3 46.3 220 16.4 
~~b) 1.46 6 76 17.3 5o.2 14.3 51.9 210 16.1 4.70 22.5 90 20.0 ~-5 1).3 41.3 140 19.0 
CP 1.55 8 68 18.1 49.8 14.1 51.7 225 16.8 
N 0.92 7 38 4.5 52.5 2.9 5.3.6 210 17.2 
6+ ~yb) 1.49 16 46 16.9 48.9 11.1 53.0 165 18.0 2.82 21 69 19.5 42.8 15.0 47.1 145 18.5 
cA(b) 2.04 13 62 17.1 48.4 13.1 52.6 185 18.0 
*Code No.: 
N • 5 to 10 minutes after alphaprodine, 5# or a+ mg/kg 
CN • Same time after anesthesia as N, but without alphaprodine 
J. • 5 minutes after propallorphan, o.25(a) or o.35(b) mg/kg 
CA • 5 minutes after propallorphan, but without the previous injection of 
alphaprodine 
CP • Same time after anesthesia as A, but without either alphaprodine or 
propallorphan 
** Statistical comparisons presented in Table 2, page 22. 
C02 % 
10 
.).0 
2.8 
1.5 
1.9 
2.9 
1.8 
2.6 
).8 
.3.4 
1.8 
).1 
2.3 
2.2 
2.4 
2.7 
Dog Code Venti-
No. No.* lation 
TABLE 3Bt The Influence of Propallorphan Following 
Alphaprodine in the Dog Under Pentobarbital** 
Blood Gases 
Resp. Vo' Arterial Venous Rate ml 
. lieart 
Rate 
L/min min o2 Vola % co2 Vola % 02 Vols % co2 Vols % 
1 2 3 4 5 6 
N TOO SEVERELY DEPRESSED FOR MEASUREMENTS 
r ~~b) l.a6 8 37 1.35 5 64 CA(b) 1.29 7 38 
N 1.20 7 37 
a• ~~b) 1.46 10 6o 5.93 28 132 
CP 1.70 10 48 
N 1.20 14 48 
~ ~yb) 1.46 15 49 3.87 36 65 
CP 3.92 16 137 
N 1.57 14 6o 
+ CN 1.41 7 51 
A(b) 3.14 26 69 
10 
CP 1.5o 9 54 
1 
N 0.9.3 6 4.3 
1+ ~~b) 1.18 8 48 2.27 17 90 
CA(b) 1.00 5 46 
*Code No.: See Table .3A 
**, •, (a), (b) See Table .3A 
.17.2 44.2 11.1 
19.9 .37.0 14.4 
16.0 44.4 11.1 
12.5 47.6 ;3.0 
14.6 53.4 12.6 
20.4 37.3 6.8 
15.8 51.2 13.3 
11.2 41.4 2.0 
15.0 51.6 12.0 
19.7 31.0 5.1 
16.9 48.8 12.6 
14.8 5o.o 10 • .3 
19 • .3 52.6 15.6 
20.5 42.8 16.0 
17.2 52.6 1.5.8 
10.1 57.8 8.1 
14.5 58.6 9·9 
16.5 55.6 7.3 
14.0 61.4 9.1 
7 8 
53.6 210 
43.6 145 
53.0 200 
51.3 15o 
52.8 16o 
52.8 1~ 
53.0 16o 
48.1 2~ 
52.7 m 
43.5 200 
52.0 ~0 
52.0 18o 
55.2 165 
48.4 190 
53.8 180 
57.0 1~ 
61.5 170 
56.0 16o 
62.~ 165 
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~ired 
Air 
02 % po2 % 
9 10 
18.1 2.2 
17.5 3.0 
18.1 2.2 
18.0 2.1 
17.1 2.5 
18.8 1.7 
18.3 1.9 
17.9 2.1 
17.8 2.3 
19.3 1.5 
17.4 3.0 
17.4 2.4 
17.3 3.0 
18.8 1.7 
17.4 .3.4 
16.7 2.6 
17.1 2.8 
17.2 3.0 
16.7 2.6 
TABLE 4: Statistical Comparison of the Measurements 
Presented in Tables .3A and 3B by Paired Data Analysis 
Blood Gases 
Comparisons Venti- Resp. ~, Arterial Heart Venous (Code Ro. *) lation Rate Rate 
L/Dlin min 02 C02 02 C02 
CR cf. R <{).02** N.s. *** N.s. <0.05 N.S. <0.01 N.s. N.s. 
H cf. A <i>.Ol <0.01 <i>.Ol <0.01 <0.05 <0.01 N.s. N.s. 
CN cf • .A <0.01 <0.01 N.s. <0.01 <0.05 H.S. fO.Ol N.s. 
CN cf. CA N.S. N.S. N.s. N.s. N.S. N.s. N.s. N.s. 
CN cf. CP N.S. N.S. N.s. N.s. N.S. N.s. N.s. N.s. 
* Code No.: See Table 3A 
**Probability of difference or significance 
*** N. s. • Not significant 
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Expired 
Air 
02 C02 
N.s. N.s. 
<0.01 <0.05 
<0.02 <0.02 
x.s. N.S. 
N.s. N.s. 
FIGURE 3 
Mean effects of alphaprodine alone and given simultaneously with 
propallorphan (Ro-1-7780) on nine dogs 
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(4 or 5 mg. /kg.) produced a severe respiratory depression which lasted 
for about 12 to 15 minutes; three of the eight animals, in fact, required 
artificial respiration for 1 to 7 minutes. When propallorphan was given 
contemporaneously with alphaprodine in the same animals, respiratory 
rate was significantly higher during this critical period (20 of. 5 
breaths/minute), as were minute ventilation (1. 45 of. o. 45 L/min.) and 
arterial oxygenation (19. 2 of. lS. 2 vols. %) • Statistical analysis of 
these data showed that propallorphan was effective in controlling the 
respiratory depression of alpbaprodine. Although a significant difference 
existed between the narcotic alone and the combination in regard to 
respiratory rate ( 14 cf. 9 breaths/minute) 25 to 35 minutes after drug 
injection, the minute ventilation was not significant~ different at 
this time. The figures for arterial oxygenation include the three dogs 
that were artific~ ventilated after alphaprodine alone; nevertheless, 
the mean oxygenation was significantl.Jr better in the group receiving the 
combined medication. 
The effects of morphine and propallorphan on ventilation vol'IDfte in 
seven anesthetized dogs is presented in Figure 4. In all experilllents 
propallorphan reversed the respiratory depression produced by' morphine. 
In two of these experiments o. 2 mg. /q. of the antagonist arouaed the 
animals to such an extent that measur•ents had to be discontinued. 
Therefore, the results presented in Figure 3 represent the average changes 
in minute ventilation for eleven of the thirteen experiments. 
In Figure 4 the percent of control minute ventilation corresponds 
to the anesthetic agent alone and is taken as 100 percent for each animal. 
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FIGURE 4 
Mean duration of effect of pro~allorphan (Ro-l-778o) on minute ventilation 
after morphine on seven dogs 
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0 
-10 /0 ~0 30 ;o .so 
TIME JN MINUTES 
Time in minutes 
-10 0 10 20 
Mean percent 85 85 127 122 11.3 lll7 110 98 91 95 I 96 
' S.L .3 3 8 10 9 12 11 5 4 4 I 4 
·"P" of difference 
compared to <0.01 <0.01 <0.01 <0.05 N. s. * N.s. N. s. N.s. u.s. N. s. N. S. 
control 
----- --- ---~-
"P" of difference 
compared to .. 
-
<0.01 <0.01 <0.02 <0.011<0.05 <0.05 N. S. I N. S. N. s. 
morphine alone I 
N.S. • Not significant 
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This is shown as the first column at the left. In the next two colUJIDla 
from the left, the effect of morphine is shown 10 and 5 minutes before 
propallorpban was injected. The opiate produced a significant depression 
of minute ventilation to a mean value of 85 percent of the control. The 
injection of propallorphan produced a marked increase in minute ventilation 
which was significantly higher than the control value for the first 10 
minutes only, and vas significantly' above that or morphine for a total of 
}) minutes after propallorphan was injected. Be70J1d this point the 
depression previously produced by lllOrphine was reinstated. 
Respiratory rate and heart rate did not change significantly in 
these experiments. In addition, no significant difference in effect was 
. 
found between o.oa or o. 2 rag./kg. of propallorphan; and since only one 
dose of the antagonist of 1 mg./kg. could be tried (suppl.7 of propall-
orphan exhausted), statistical evaluation between this dose and the other 
tw was not possible. In one dog given morphine, nalorphine (1 mg./kg.) 
was injected after the opiate and produced an effect comparable to what 
was seen with propallorphan. 
2. Human Studies: 
(a) .A.lpbaprodine series : 
This study' clearly" indicated that within a critical range of 
ratios the addition of progressively increasing proportions of either 
levallorphan or propallorphan to the narcotic was accompanied by an 
increasing protection against respiratory depression while effective 
analgesia persisted. Increasing the amoUI'lt of either antagonist above 
this ratio produced no further change in respiration, but side effects 
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increased markedly. No appreciable alterations in pulse or blood 
pressure were noted after any of the drugs or combinations used. The 
actions of the narcotic alone and of the antagonist-narcotic combina-
tions which were considered most important are summarised in Figures 5, 
6, and 7 and in Tables 5 through 8. Pertinent statistical data appear 
in Tables 9 through 14. Since the extreae doses and ratios showed no 
significant difference in the respirator, picture than the most 
effective ratios, and because of the quantity and complexity of the 
results, they are not included in the tables and figures. 
The six subjects who received saline showed very small changes 
(less than 10%, if any) in respiratory rate, minute ventilation or tidal 
voluae from their normal values during the period of observation. The 
minor fluctuations seen were neither consistent nor statistically signifi• 
cant. These patients remained quiet and cooperative for the most part, 
but none of thea tell asleep • 
.After alphaprodine alone, o. 375 mg. /kg. , the average minute ventila-
tion fell to 60 percent of no:nu.l (Figures 5C and D, and Table 6) within 
2 minutes, but returned nearly to the normal within 20 minutes. Minute 
ventilation was significantly lower after this medication than after 
saline for the first 15 minutes (Table 9). This dose of alpbaprodine 
produced some decrease in respiratory rate (Figures 6C and D, and 
Table 7) which was significant for the 5, 10, and 15 minute periods 
(Table 10), while tidal vol'IDile (Figures 7C and D, and Table 8) was not 
significantly altered (Table 11). .As to responsiveness, the patients 
FIGURE 5 (A,B,C,D) 
Minute inspiratory ventilation following alphaprodine alone or combined 
with levallorphan or propallorphan (Ro-1-7780)*,** 
80 
60 
<I) 40 
~ ~ 
~ 
~ 
A 
Alphoprod•ne- 0 .75mg./Kg. 
Levallorphan plus Alphoprod.ne 
o--o'o.03mg/Kg (I 25) l 
0 - 0 0 . 02 " (I 37.5) Ratio 
~....IJ 0.015 " (I 50) 
[}···{] 0 . 0075 " (I 100) 
~ 100 .---------
...... 
~ 80 
(.:) 
~ 60 
<l:: 
40 
20 
0 
- Alphoprod•ne- 0 .375 mg /Kg 
Levallorphan plus Alphoprod.ne 
Y- -1f 0 . 15 mg /Kg (I 25) 
. ..... 0 .0075 " (1 ." 50) 
5 10 15 20 25 30 
8 
- Alphoprodme- 0 . 75 mg./Kg. 
Ro 1·7780 plus Alphoprodine 
o--o 0 .03mg./Kg. (I 25) 
~.JJ 0 .015 • (1 . 50) 
~·· · <~ o :oo75 .. r 1 1oo; 
D 
- Alphoprod1ne- 0 .375 mg /Kg. 
Ro 1·7780 plus Alphoprodine 
,__,. 0.015mg./Kg. (I 25) 
. .. ... 0.0075 " (I 50) 
5 10 15 20 25 30 
MINUTES AFTER INJECTION OF DRUG(S) 
*Nine patients were given alphaprodine alone 0.75 mg./kg. and nine 
patients were given alphaprodine alone 0.375 mg./kg. Six patients 
were used for each of the combined medications. 
**In Figure $0, the 0.15 mg./kg. should read 0.015 mg./kg. 
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FIGURE 6 (A,B,C,D) 
Respiratory rate following alphaprodine alone or combined with levallorphan 
or propallorphan (Ro·l-7780)* 
80 
60 
40 
100 
80 
60 
40 
20 
A 
-- Alphaprodine- 0.7 5 mg./ Kg. 
Levallorphan plus Alphaprodinf 
o---o 0.03 mg./Kg.(l.25) J 
e--e 0.02 " (t:37.5J ~--IV 0.015 " (I. 50) Rallo 
o-----<1 0.0075 " ( 1."100) 
c 
~ Alphaprodine- 0.375 mg. /Kg. 
Levallorphan plus Alphaprodine 
.,___,.. 0.015 mg. /Kg. (I 25) 
•----- 0. 0075 " (I. 50) 
.()o __ .. 
.... 
----o--
--o(] ~----o--
B 
Alphoprodine- 0.75 mg. I Kg. 
Ro 1-7780 plus Alphaprodine 
o---o 0.03 mg./Kg. ( 1."25) 
~~ 0 015 (I. 50) 
o-----o 0.0075 " ( 1."100) 
D 
Alphaprodine- 0.375 mg./Kg. 
Ro 1-7780 plus Alphaprodine 
'f----t' 0.015 mg. I Kg. (I 25) 
........ 0. 0075 " (I ·50) 
5 10 15 20 25 30 5 10 15 20 25 30 
MINUTES AFTER INJECTION OF DRUG(S) 
*Nine patients were given alphaprodine alone 0.75 mg./kg. and nine 
patients were given alphaprodine alone 0.375 mg./kg. Six patients 
were used for each of the combL~ed medications. 
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FIGu~E 7 (A,B,C,D) 
Inspiratory tidal volume following alphaprodine alone or combined with 
levallorphan or propallorphan (Ro-1-7780)* 
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40 
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-- Alphoprodone- 0.75 r!IQ. /KQ. 
Levallorphan plus Alphaprodone 
o--o 0.03 rftQ./KQ (I 25) j 
e-e 0.02 fl J75J Rat.o 
9--fl 0015 (I 50) 
Do•••oO 0.0075 " (I 100) 
c 
- Alphaprodtne- 0.375 r!tQ/Ko 
Levallorphan plus Alplloprodone 
........ 0.015rnQ./KQ. (I 25) 
..... 0 0075 " (I 50) 
8 
Alphoprodone- 0.75mQ. /KQ. 
Ro 1· 778() plus Alphoprodine 
~ 0.03 rnQ.IKQ. (125! 
'fl-~ 015 (I 50) 
0•••<0 0.0075 " (I 100) 
·····--•--....... .. 
•• .................................. .A 
D 
- Alphoprodine -0.375rnQ./IIQ. 
Ro 1-7780 plus Alplloprodone 
\1-- 0.015 m9./KQ. (I 25) 
...... 00075 " (I 50) 
5 10 15 20 25 30 5 10 15 20 25 30 
MINUTES AFTER INJECTION OF DRUG (5) 
*Nine patients were given alphe.prodine alone 0. 75 mg./kg. and nine 
patients were given alphaprodine alone 0.375 mg./kg. Six patients 
were used for each of the combined medications. 
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.TABLE 5: Average General Responsiveness* After the Various 
Medica tiona in the Alphaprodine Series 
Dose of antagonist Responsiveness* at: 
Alphaprodine or salt solution, or 
.Ti:u in minutes after drug administration ag/kg ratio antagonist 
to alpbaprodine 
.2 5 lO 15 20 25 
0 PQysiological salt 3.0 3.0 3.0 3.0 3.0 ).0 
solution 1. 5 or 
2.0 ml 
A: Levallorphan 
0 Levallorphan: 0.075 
mg/kg 
3.0 ).0 2.5** 2.5 2.5 2.5 
0.75 0 2.0 2.0 2.0 2.0 l.S** 1.5 
1:100 1.5 1.5 1.5 1.5 1.5 1.5 
1:50 1.5 1.5 1.5 1.5 1.5 2.0 
1:37.5 2.0 2.0 2.0 2.0 2.0 2.0 
1:25 2.S 2.5 2.5 2.5 2.5 ).0 
0.375 0 2.5 2.5 2.5 2.5 2. 5 2.5 
1:50 2.5 2.0 2.0 2.0 2.0 2.0 
1:25 2.5 2.0 2.0 2.0 2.0 2.0 
B. PropallorphaD 
0 Propallorphan: 0.0375 or 
0.075 mg/kg 
2.5 2.0 2.0 2.0 2.0 2.5 
0.75 1:100 2.0 1.5 1.5 1.5 1.5 2.0 
1:50 2.0 2.0 1.5 1.5 1.5 2.0 
1:25 2.0 2.0 2.0 2.0 2.0 2.0 
0.375 1:5o 2.5 2.0 2.0 2.0 2.0 2.0 
1:25 2.5 2.0 1.5 1.5 2.0 2.0 
* General responsiveness evaluated by objective observation of patients: 
4 • exci teaent 2 • asleep and easily aroused 
3 • same as before drug 1 • asleep and aroused with difficulty 
administration 
** Values of 1. 5 and 2. 5 were arrived at by averaging the individual results and 
rounding oF to thenearest o. 5 unit. 
)) 
).0 
2.5 
1.5 
1.5 
2.0 
2.0 
3.0 
2.5 
2.0 
2.5 
2.5 
2.0 
2.0 
2.0 
2.5 
2.5 
TABLE 6: Means and Standard Errors of Observations on Inspiratory 
Minute Ventilation in the A.lpbaprodine Series 
* Means and standard errors at: 
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Dose of antagonist 
.Alphaprodine or salt solution, or 
mg/kg ratio antagonist 
to alphaprodine 
Time in minutes after drug administration 
2 5 1 10 1 15 1 20 1 25 1 ~ 
0 Physiological salt 98t2 97t3 
solution 1. 5 or 
2.0 ml 
A: Levallorphan 
0 Levallorphan: o. 075 9()t9 94t3 
ag/kg 
98:!:6 98t4 97t2 JD2t2 98t2 
0.75 0 sot6 se>t3 6¢4 6?t3 74:!:4 7¢5 86:!:4 
1:100 52t3 64t3 76t5 8Jt7 9Jt5 96t4 99t4 
1:SO 53:!:4 75t6 88t6 99:!:2 98t2 97:!:3 9¢3 
1:37.5 76t10 82t7 96t6 96t8 88t4 94t) 97i:2 
1:25 96t5 94±4 9?t2 100±2 102±1 J.OOt1 100t1 
0.375 0 59!4 6)!6 7lt8 8)t8 90t6 9:¢6 99!2 
1:5o 7Jtll 86!9 86:!:9 88t8 84:!:8 95t6 88t7 
1:25 89t5 92*4 94t4 88t4 98t6 96t.3 97:!:4 
B: Propa11orphan 
0 Propa1lorpban: 0.0375 or 98:!:4 97t2 
0.075 mg/kg 
100:!:2 100:!:4 98:!:3 l.Olt) 99:!:1 
0.75 1:100 59!4 60t4 68t4 74:!:4 77:!:4 86!5 9Jt4 
l:5o 57:!:8 82:!:4 86:!:5 90:!:5 88:!:6 94:!:4 95±3 
1:25 92t4 92t4 981:4 9S:!:4 lOOt) 99t3 105%5 
0.375 1:5o 78:!:4 8;!4 91:!:4 96:!:2 98t1 102:!:1 98:!:1 
1:25 85t2 89t3 96t5 95t5 100t4 99:!:4 102t4 
* Means are expressed as percent of control. 
TABLE 7: Means and Standard Errors of Observations on Respiratory 
Rate in the Alpbaprodine Series 
Dose of antagonist Means*and standard errors at: 
Alphaprodine or salt solution, or 
mi/kg ratio antagonist Time in minutes after drug administration 
to alpbaprodine 
2 I , I ;10 I lS 120 I 2, 1 .30 
0 Phfsiologieal salt 9~3 102±4 102t4 ]00!3 95±2 97±2 95!4 
solution l.. S or 
2.0 ml 
A: Levallorphan 
0 Levallorphan: 0.075 9Q±6 92!4 96!2 97±2 92'!8 9st4 95t5 
mg/kg 
0.75 0 7J!S 7o!S 78iS sots 8st4 87±6 92±6 
1:100 67!4 76±5 78!6 84±10 88±8 92±9 94±7 
l:SO 66!11 7¢15 78±7 8)!6 84±7 86±9 87±10 
1:37.5 8)!10 8¢9 92i6 94±4 88±4 97±6 96t8 
1:25 87t6 88t4 90±5 95t6 98tS 98t6 lOOtS 
0.375 0 7:¢5 7¢6 76!5 80±4 87±3 91±5 94±2 
l:SO 100!7 101±7 98t6 9~8 10¢7 107±9 101!8 
1:25 100±11 95:!:8 99:!:10 100±6 97±9 96tl0 10l:t8 
B: Propallorphan 
0 Propallorphan: 0.0375 or 98!6 96!4 97!5 102!7 101±6 101!7 101:!:7 
o.o7S mg/kg 
o.7S 1:100 S¢8 70±13 68!9 74:!:7 78!S 7¢7 82:!:7 
l:SO 62±9 88:!:15 81±8 80:!:9 84:!:9 86tll 88:!:8 
1:25 8¢7 88±5 88±4 84!4 90±4 90!4 9¢4 
0.375 l:SO 85±9 84±8 9JtS 92:!:6 94:!:5 96:!:5 94±6 
1:25 84t9 102tll 10otll 98tS 99:!:5 10 )tll 10 3:!:7 
* Means are expressed as percent of control. 
. TABLE 8: Means and Standard Errors of Observations on Inspiratory 
Tidal Volume in the Alphaprodine Series 
Dose of antagonist * -Means and standard errors at: 
41 
Alphaprodine or salt solution, or 
mg/kg ratio antagonist Time in minutes after drug administration 
to alpbaprodine 
.2 I 5 I -10 I 15 I 20 1 25 I )) 
0 Physiological salt 102!4 98!7 _100:!:5 98!6 .10¢7 98!4 99!4 
solution 1. 5 or 
2.0 a1 
A: Levallorphan 
0 Levallorphan: o.o75 98t6 10lt4 99:!:5 98:!."2 104!:6 10'7!5 10:¢6 
mg/kg 
0.75 0 68t6 72!4 87!6 86t6 88:!:7 92!6 94!:6 
1:100 78±6 86!8 9¢12 102t10 108t11 110tu 101!10 
1:50 102!28 110t20 115t10 12,3t11 12ltl2 116tl1 120*11 
1:37.5 101tl5 1041:13 108t8 1041:7 102t7 lOOt$ 1071:11 
1:25 10$t8 104t6 110t7 98!6 102t4 102t6 102t7 
0.375 0 86!6 86!8 97!10 107:!:10 10$!8 103!6 106!:5 
1:$0 72:!:11 84:!:7 87!7 90!8 76!7 86%5 86!5 
1:25 90:!:7 97:!:5 100:!:6 89:!:6 102:!:10 102:!:9 96±8 
B: Propallorphan 
0 Propallorphan: 0.0375 or 101±8 100:!:4 104:!:7 98:!:5 97:!:4 101:!:7 100:!:6 
0.075 mg/kg 
0.75 1:100 82!:8 92~7 96!9 98!:6 100!5 109!4 106t2 
1:50 93!15 94tl3 102:!:11 112:!:19 100:!:8 110:!:17 106114 
1:25 107tll 10li8 106t7 1081:7 107%3 106t6 106t5 
o.37S 1:50 91±5 99:!:4 94!6 104±6 10;±4 101:!:4 10lt4 
1:2S 10Qt10 88t9 95±6 89:!:7 95:!:5 87:!:6 92tS 
* Means are expressed as percent of control. 
* TABLE 9: Statistical Comparison of the Effects of Alphaprodine and Saline 
to the Effects of Alphaprodine-Antagonist Combinations on Inspiratory 
Minute Ventilation 
Ratio 
Probability of difference, or significances Dose Antagonist 
Tille in llinutes after drug administration to 
_I J 1 I ag/kg Alpbaprodine 2 5 10 15 20 25 ~ 
1.. Alphaprodine 0.75 mg/kg compared to: Alphaprodine vi th 
Levallorphan 
N.S. ** <0.01 N.S. <0.01 <0.01 <0.01 <0.01 0.375 0 
N.s. <0.01 N.s. <0.05 <0.05 <0.02 <0.02 0.15 1:100 
N.s. <0.01 <0.01 <0.01 <0.01 <0.02 <0.05 l:SO 
<0.05 <0.01 <0.01 <0.01 <0.05 <0.05 N.s. 1:37.5 
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.05 1:25 
Alphaprodine vi th 
Prop all orphan 
N.s. N.s. N.s. N.S. N.s. N.S. N.s. 0.75 1:100 
N.s. <0.01 <0.01 <0.01 <0.05 <0.05 N.S. 1tSO 
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.02 1:25 
2. Alphaprodine o. 375 mg/kg compared to: Alpbaprodine with 
Levallorphan 
N.s. <0.05 N.s. N.s. N.s. x.s. N.S. 0.375 l:SO 
<0.01 <0.01 <0.02 N.S. N.s. N.s. N.s. 1:25 
Alphaprodine with 
Propallorphan 
<0.01 <0.01 <0.05 N.s. N.s. N.S. N.S. 0.375 l:SO 
<0.01 <0.01 <0.02 N.S. N.s. N.S. N.s. 1:25 
3. Saline solution 1.. 5 or 2 m1 compared to: Alphaprodine wi. th 
Levallorphan 
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 N.s. 0.15 0 
<0.01 <0.01 <0.01 N.s. w.s. w.s. N.S. 1:100 
<0.01 <0.01 N.s. N.s. N.s. N.s. N.S. 1:SO 
N.s. N.s. N.S. N.s. N.S. N.s. N.S. 1:37.5 
N.s. N.S. N.S. N.s. N.s. N.S. N.s. 1:25 
<0.01 <0.01 <0.01 <0.02 N.s. N.s. N.S. 0.375 0 
<0.02 N.s. N.S. N.s. w.s. N.S. N.s. l:SO 
w.s. N.S. N.s. N.S. N.S. N.S. N.s. 1:25 
Alphaprodine with 
Propallorphan 
<0.01 <0.01 <0.01 <0.01 <0.01 N.S. N.S. 0.15 1:100 
<0.01 <0.01 <0.01 w.s. N.s. N.s. N.S. 1:SO 
<0.02 N.s. N.S. N.s. N.S. N.S. w.s. 1:25 
<0.01 <0.02 <0.02 N.S. N.s. N.s. N.S. 0.375 l:SO 
<0.01 N.s. N.S. N.s. N.s. N.s. N.S. 1:25 
* by "t" test of "Student" ** N. s. • Not significant 
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TABLE 10: Statistical Comparison* of the Effects of Alphaprodine and Saline 
to the Effects of A.lphaprodine-Antagonist Combinations on Respiratory Rate 
~robability of difference, or significance: 
Ratio Tille in minutes after drug administration Dose 
.Antagonist 
I mg/kg to 2 5 10 15 20 25 ~ Alphaprodine 
.1. Alphaprodine o. 15 mg/kg compared tot ,Alphaprodine with 
Levallorphan 
N.s.'** N.s. N.s. N.s. N.s. N.s. N.s. 0.375 0 
N.s. N.s. N.s. N.s. N.S. N.S. N.s. 0.75 1:100 
N.s. N.s. N.s. N.s. N.s. N.s. N.S. 1:50 
N.S. N.s. N.s. N.s. N.s. N.S. x.s. 1:31.5 
N.S. <0.05 N.S. N.s. <0.05 NeS. N.S. 1:25 
Alphaprodine with 
Propallorphan 
N.s. N.s. N.s. N.s. x.s. N.S. N.S. 0.75 1:100 
N.S. N.S. N.s. N.s. N.S. N.S. N.s. 1:50 
H.s. N.s. w.s. N.S. N.S. N.s. N.S. 1:25 
2. Alpbaprodine 0.375 mg/kg compared to: Alphaprodine with 
Levallorphan 
<0.01 <0.01 <0.02 <0.05 <0.01 <0.05 N.S. 0.315 1:50 
<0.02 <0.02 <0.05 <0.02 <0.02 N.S. N.S. 1:25 
Alphaprodine with 
Prop all orphan 
N.S. N.S. <0.05 N.s. N.s. N.S. N.s. 0.375 1:50 
N.s. <0.05 <0.05 <0.05 N.s. N.S. N.s. 1:25 ·, 
). Saline solution l.. 5 or 2.0 al compared toa Alphaprodine vi th 
Levallorphan 
<0.01 <0.01 N.s. N.s. N.s. N.S. N.S. 0.75 0 
<0.01 <0.01 <0.01 N.s. N.S. N.S. u.s. 1:100 
<0.01 N.s. <0.01 <0.01 N.S. N.s. N.S. la50 
N.s. <0.05 N.s. N.s. N.s. N.s. N.S. 1:37.5 
N.s. <0.01 N.S. N.s. N.S. N.s. N.S. 1:25 
N.S. <0.01 <0.01 <0.01 N.s. N.s. N.S. 0.375 0 
I.S. N.S. N.s. N.s. N.s. N.S. N.s. lt50 
N.S. w.s. N.s. N.s. N.S. N.S. N.S. 1:25 
Alphaprodine with 
Propallorphan 
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.05 0.15 1:100 
<0.01 N.S. <0.01 <0.02 N.S. N.s. N.S. 1:50 
N.s. <0.02 <0.01 <0.01 <0.01 N.s. N.S. 1:25 
N.s. <0.05 N.S. N.s. N.S. N.s. N.S. 0.375 1:50 
N.s. N.s. N.S. N.S. N.s. N.S. N.S. 1:25 
*, ** See notes Table 9 
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TABLE 11: Statistical Comparison* of the Effects of Alphaprodine and Saline 
to the Effects of' Alphaprodine-Antagonist Combinations on Inspiratory 
Tidal VolUII.e 
Probability of difference, or significance: 
~atio Time in minutes after drug administration Dose 
Antagonist 
2 I 5 I 10 1 .15 I I 25 1):) mg/kg to 20 Alphaprodine 
1. Alphaprodine o. 75 mg/kg compared tot . Alphaprodine with 
Levallorphan 
<0.01 N.s. ** N.s. <0.01 <O.o5 N.s. N.s. 0.375 0 
N.s. N.s. N.s. N.S. N.s. N.s. N.s. 0.75 1:100 
N.s. <O.o5 <0.02 <0.01 <0.01 <O.os <O.os 1:5o 
<0.05 <0.01 N.s. N.s. N.s. N.s. N.s. 1:37.5 
<0.01 <0.01 <0.01 N.s. N.S. N.s. N.S. 1:25 
Alphaprodine with 
N.s. <O.o5 N.s. N.s. N.s. 
Propallorphan 
N.s. N.s. 0.75 1:100 
N.s. N.s. N.s. N.s. N.S. N.s. N.S. 1:5o 
<0.01 <0.01 <O.o5 <O.o5 <O.o5 N.s. N.S. 1:25 
2. Alphaprodine 0.375 mg/kg compared to: Alphaprodine with 
Levallorphan 
N.S. N.s. N.S. N.S. <O.o5 N.s. N.s. 0.375 1:5o 
N.s. N.s. N.s. N.s. N.S. N.S. N.s. 1:25 
Alpbaprodine with 
Propallorphan 
N.S. N.s. x.s. N.S. x.s. N.s. N.s. 0.375 lt5o 
N.s. N.s. N.s. N.S. N.s. N.S. N.S. 1:25 
3. Saline solution 1. 5 or 2.0 Ml compared to: Alpbaprodine with 
Levallorphan 
<0.01 <0.01 N.s. N.s. N.S. N.s. N.s. 0.75 0 
<O.o5 N.s. N.S. N.s. N.s. N.s. M.s. 1:100 
N.s. M.S. N.s. <0.02 N.S. N.s. <0.05 It 5o 
N.s. N.s. N.s. N.S. N.S. N.s. N.s. 1:37.5 
N.s. N.s. N.S. N.s. N.s. N.s. N.S. 1:25 
N.s. N.s. N.s. N.S. N.s. N.s. N.s. 0.375 0 
<0.01 N.s. N.S. N.s. <0.01 <O.o5 <0.05 1:5o 
N.s. N.s. N.S. N.S. N.S. N.S. N.S. lt25 
Alphaprodine with 
Propa11orphan 
<0.01 N.s. N.s. u.s. N.S. <O.o5 <0.05 0.75 1:100 
N.S. N.s. N.s. N.S. N.S. N.S. N.S. 1:5o 
N.s. N.S. N.S. N.S. N.S. N.S. N.S. 1:25 
<O.o5 N.s. N.s. N.s. N.s. N.s. N.s. 0.375 l:SO 
N.S. N.s. N.S. N.S. N.S. <O.os N.S. 1:25 
*t ** See notes Table 9 
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TABLE 12: Statistical Comparison* of Inspiratory Minute Ventilation After 
Various Combinations of Alpbaprodine with Antagonists 
Probability of difference, or significance: Ratio 
Time in minutes after drug administration Dose Antagonist 
2 I 5 I lO J 15 I 201 25 I 3) mg/kg 
to 
Alpbaprodine 
1. .A.lphaprodine o. 7 5 mg/kg and levallorphan 1: 100 Alphaprodine with 
compared to: Levallorphan 
N.s.** N.s. N.s. N.S. N.s. N.S. N.s. 0.75 1:~ 
<O.o5 <O.o5 <O.o5 N.s. N.S. N.S. N.s. 1:37.5 
<0.01 <0.01 <0.01 <0.01 <0.01 N.S. N.S. 1:25 
2. Alphaprodine 0.75 mg/kg and levallorphan 1:~ Alphaprodine with 
compared to: Levallorphan 
N.s. N.s. N.s. N.s. N.s. N.s. N.s. 0.75 1:37.5 
<0.01 <0.02 N.s. N.s. N.S. N.s. N.S. 1:25 
3. Alphaprodine o. 75 mg/kg and levallorphan 1:37.5 Alphaprodine vi th 
compared to: Levallorphan 
N.s. N.s. N.s. N.S. <0.02 N.s. N.s. o.75 1:25 
4. Alphaprodine 0. 375 mg/kg and levallorphan 1: ~ Alphaprodine with 
compared to: Levallorphan 
N.s. N.s. N.s. N.s. N.s. N.s. N.S. 0.375 1:25 
1. Alpbaprodine o. 75 mg/kg and propallorphan 1:100 Alphaprodine with 
coapared to: Propallorphan 
N.s.** <0.01 <0.01 <0.01 N.s. N.s. N.s. 0.75 1:~ 
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 1:25 
2. Alphaprodine o. 75 mg/kg and propallorphan 1: ~ Alphaprodine with 
compared to: Propallorphan 
<0.01 <O.o5 <O.o5 N.S. <O.o5 N.s. <O.o5 o.75 1:25 
3. Alphaprodine o. 375 mg/kg and propallorphan 1: So Alphaprodine vi th 
COIIp&red to: Propallorphan 
N.s. N.s. N.s. N.S. N.s. N.s. N.s. 0.375 1:25 
*,** See notes Table 9 
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* 'l'.A.BLE 13:: Statistical Comparison of Respiratory Rate After Various 
Combinations of Alphaprodine with Antagonists 
Probability of difference, or significance: Ratio 
Time in minutes after drug administration Dose 
.A.niagonist 
to 
2 5 10 15 20 25 ~ mg/kg Alphaprodine 
1. .A.lphaprodine o. 75 mg/kg and levallorphan 1:100 Alphaprodine with 
compared tot Levallorphan 
N.s.** N .• s. N.s. N.S. N.s. N.s. N.S. o.75 1:50 
N.S. N.S. <0.05 N.s. N.s. N.s. N.s. 1:37.5 
<0.01 <O.o5 N.S. N.s. N.S. N.s. N.s. 1:25 
2. Alphaprodine 0. 75 mg/kg and levallorphan 1:50 Alphaprodine with 
compared to: Levallorphan 
N.s. N.s. N.S. N.s. N.s. N.s. N.S. 0.75 1:37.5 
<0.05 N.s. N.s. N.s. <O.o5 N.s. N.s. 1:25 
3. Alpbaprodine 0.75 mg/kg and levallorphan 1:37.5 A.lphaprodine with 
compared to: Levallorphan 
N.s. N.S. N.s. N.s. N.S. N.S. N.s. 0.75 1:25 
4. Alphaprodine o. 375 mg/kg and levallorphan 1:50 Alphaprodine with 
compared to: Levallorphan 
N.s. N.s. N.s. N.s. N.s. N.s. N.s. 0.315 1:25 
1. Alphaprodine o. 75 mg/kg and propallorphan 1:100 Alphaprodine with 
compared to: Propallorphan 
N.s. N.s. N.S. N.s. N.S. N.s. N.S. 0.75 1:50 
<0.01 N.S. N.S. N.S. <O.o5 N.s. <O.o5 1:25 
2. Alphaprodine o. 75 mg/kg and propallorpban 1:50 Alphaprodine with 
compared to: Propallorphan 
<0.02 N.s. N.s. N.s. N.S. N.s. N.S. 0.75 1:25 
3. Alphaprodine 0. 375 mg/kg and propallorphan 1:50 Alphaprodine with 
compared to: Propallorphan 
N.S. N.S. N.s. N.S. N.s. N.s. N.s. 0.375 1:25 
*,** See notes Table 9 
TABLE 14: Statistical Comparison* of Inspiratory Tidal VolURle After 
Various Combinations of Alphaprodine with Antagonists 
frobability of difference, or significance: 
Ratio Time in minutes after drug administration Dose 
Antagonist 
I I I I 20J mg/kg to 2 5 lD 15 25 )) Alphaprodine 
1.. Alphaprodine o. 75 mg/kg and levallorphan 1:100 Alphaprodine with 
compared to: Levallorphan 
N.S. ** NeS. w.s. N.s. N.S. N.S. N.S. 0.75 1:5o 
N.s. N.S. N.S. N.S. N.S. N.S. N.S. 1:37.5 
<.0.01 <.0.05 N.s. N.S. N.s. N.S. N.S. 1:25 
2. .A.lphaprodine 0. 75 mg/kg and levallorphan 1:.5o Alphaprodine with 
compared to: Levallorphan 
N.s. N.s. N.s. N.s. N.S. N.s. N.S. 0.75 1:37.5 
N.S. N.S. N.s. <.0.05 N.s. N.s. N.s. 1:25 
3 • .A.lphaprodine 0.75 mg/kg and levallorphan 1:37.5 .A.lphaprodine with 
compared to: Levallorphan 
N.s. N.S. N.s. N.s. N.s. N.S. N.S. o.75 1:25 
4. Alpbaprodine o. 375 mg/kg and levallorphan 1:5o Alphaprodine with 
compared to: Levallorphan 
N.s. N.s. N.S. N.S. <.0.02 N.S. N.S. 0.375 1:25 
1.. A1phaprodine o. 75 ag/kg and propallorphan 1:100 Alphaprodine with 
compared to: Propallorphan 
N.S. N.s. N.s. N.s. N.S. N.S. N.s. 0.75 1:50 
<0.01 N.s. N.s. N.s. N.s. N.s. N.S. 1:25 
2. Alphaprodine o. 75 mg/kg and propallorphan 1:5o Alphaprodine with 
compared to: Propallorphan 
N.s. N.S. N.s. N.S. N.s. N.s. N.S. 0.75 1:25 
). .A.lphaprodine o. 375 mg/kg and propallorphan 1: 5o .A.lphaprodine with 
compared to: Propallorphan 
N.s. N.S. N.s. <0.05 N.S. <0.05 N.S. 0.375 1:25 
*, ** See notes Table 9 
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were drowsy or light~ asleep during the entire observation period 
(Table 5, page 38) • 
.Alphaprodine, 0. 75 mg. /kg., produced an average fall in minute 
ventilation to 5o percent of the norraal in the first 2 minutes (Figures 
5A and B, page 35; and Table 6, page 39). The ventilation remained 
significantly lower than that after saline or after the 0.375 mg./kg. 
dose of the drug for 25 to 30 minutes (Table 9, page 42). The higher 
dose thus produced a more severe and prolonged depression of ventilation 
than the lower dose. The respiratory rate fell to 70 percent of the 
normal during the first 5 minutes (Figures 6A and B, page 36; and Table 1, 
page 40) and gradually returned to pre-injection levels. Although the 
rate did not differ significantly from that following the low dose of 
alphaprodine, it was significantly lower than that in the saline 
controls during the first 10 minutes (Table 101 page 43). Tidal volume 
(Figures 7A and B, page 37; and Table 8, page 41) 1 although variable, 
was significantly below the controls for the first 5 minutes on~ and 
significantly lower than the low dose of the narcotic at the 2, 15, and 
20 minute periods (Table 11, page 44). Responsiveness was depressed 
to a point where most of the patients were asleep but aroused with ease 
(Table 5, page 38), and they did not react particularly to the experi-
mental manipulations. 
As to the antagonists by themselves, neither levallorphan nor 
propallorphan had any effect on respiration (Tables 6, 7, and 8, pages 
39, 40, and 41). Although levallorphan (0.075 mg. /kg.) had no appreciable 
effect on responsiveness, propallorphan (0.0375 or 0.075 mg./kg.) produced 
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depression to a point where the patients were drowsy or lightly asleep 
(Table 5, page 38). 
These observations on the effects of saline solution, alphaprodine, 
and the antagonists afforded a basis for evaluation of the combined effect 
of alphaprodine and the antagonists given together. 
The combined effect of propallorpban (Ro-1-7780 with alphaprodine 
in ratios of 1:100, 1:5o and 1:25 is shown in Figures 5, 6, and 7B and 
D; pages 35, 36, and 37; and in Tables 5 through 8, pages .38 - 41; the 
statistical findings are detailed in Tables 9 through 14, pages 42 - 47. 
When propallorphan was administered in ratios of 1:5o and lt25 to alpha-
prodine at a dose of o. 75 mg./kg., the inspiratory ventilation was 
significantly greater than that following the narcotic alone; the 1:100 
combination produced no significant change in ventilation (Table 9, page 
42). In addition, when these three ratios were compared to one another, 
each was significantly different from the other (Table 12, page 45). 
·Thus, ventilation was progressively improved as the amount of propallorphan 
added was increased in the experiments in which o. 75 mg. /kg. of alpha-
prodine was used. On the other hand, respiratory rate was not affected 
when the antagonist was added and coBpared to the narcotic alone (Table 10, 
page 43); but the 1:25 ratio was significantly better than the 1:100 
ratio at the 2, 20 and 30 minute periods (Table 13, page 46). In regard 
to inspiratory tidal volume, only the 1:25 ratio produced a significant 
improvement over the o. 75 mg./kg. dose of the narcotic alone (Table 11, 
page 44) , while the three ratios were not significantly different from 
each other (Table 14, page 47). When they were compared to the saline 
49 
controls, the 1:100 and 1:50 ratio were significantly different in regard 
to ventilation (Table 9, page 42); all three ratios were significantly 
below physiological saline in regard to respiratory rate (Table 10, page 
43), and tidal volume showed differences with respect to the 1:100 ratio 
only at the 2, 25, and 30 minute periods (Table 11, page 44). General 
responsiveness remained in "the range of 1. 5 to 2. 5 for all ratios of the 
combined medication (Table 5, page .38). 
When propallorphan was combined vi th alphaprodine ( o. 37 5 mg. /kg.) 
at ratios of 1:50 and 1:25 and compared to the low dose of the narcotic, 
neither ratio produced a significant improvement in tidal volume (Table 11, 
page 44), but improvement in respiratory rate was produced at the 5, 10, 
and 15 minute periods for the 1:25 ratio (Table 10, page 43). On the 
other hand, inspiratory ventilation was significantly above the narcotic 
alone for the first 10 minutes after both ratios (Table 9, page 42). 
When these two ratios were compared to the saline controls, no difference 
was demonstrated, except for ventilation with respect to the 1:50 ratio 
only (Tables 9 through 11, pages 42 - 44). When the ratios were compared 
to each other, no consistent significant difference was found (Tables 12 
through 14, pages 45 - 47). 
It can therefore be said that propallorphan combined with either 
the low dose (0.315 mg./kg.) or the high dose (0.75 mg./kg.) of alpha• 
prodine at a ratio of 1:25 did not produce any respiratory depression. 
The effects of combining levallorphan with alphaprodine at 0.75 JRg./ 
kg. in ratios of 1:25, 1:37.5, 1:50, and 1:100 are shown in Figures 5, 6, 
and 7A, pages 35, 36, and 31; and in Tables 5 through 8, pages 3S - 41; 
the statistics are presented in Tables 9 through 14, pages 42 - 47. At 
the higher ratios of antagonist (1:25 and 1:37.5) the ventilation did 
not differ from that following physiological saline, while it was signifi-
cantly different from the narcotic alone (Table 9, page 42). B7 contrast, 
the lt 5o and 1:100 ratios showed differences from both the saline and 
narcotic controls. Although respiratory rate was not significantq 
different between the four ratios and the alphaprodine controls, the 
1:50 and 1:100 ratios show differences for the first lO or 15 minutes 
when conpared to the saline controls (Table 10, page 43). With respect 
to tidal volume, differences appeared between the ratios 1:50, 1:37.5, 
and 1:25 and the narcotic alone, but no constant difference existed when 
compared to physiological saline (Table 11, page 44). When these ratios 
were compared to each other, no consistent difference was found for tidal 
volume or respiratory rate, except for the conparison between 1: lOO and 
1:25. Here they were different tram each other for the first two periods 
after drug administration (Tables 13 and 14, pages 46 and 47). In terms 
of minute ventilation the 1:25 and 1:37.5 ratios were different from 
1:100, and the 1:50 and 1:25 show differences at the 2 and 5 minute periods 
only (Table 12, page 45). 
The effects of combining alphaprodine with levallorphan at 0.375 m&-/ 
kg. in ratios of 1:50 and 1:25 are presented in Figures 5, 6, and 7C, 
pages 35, 36, and 37; and Tables 5 through 14, pages 38 - 47. When these 
two ratios were conpared to the low dose of the narcotic alone, minute 
ventilation was effectively inproved b.Y the 1:25 ratio only (Table 9, page 
42), respiratory rate was inproved by both ratios (Table 10, page 43), 
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and tidal volume was not changed by either {Table 11, page 44). In these 
same tables it can be seen that neither ratio was consistently different 
from saline controls for either ventilation, rate, or tidal volume; nor 
were the ratios different fran each other (Tables 12, 13, and 14, pages 
45, 46, and 47). 
Following the various combinations of alphaprodine with levallorphan 
the patients remained drowsy; but responsiveness was in the range of 
2 to 2.5 for the 1:25 and higher ratios, while for the narcotic alone or 
with lower antagonist ratios, responsiveness averaged between 1. 5 and 
2.0 (Table 5, page 38). 
Combinations of levallorphan and alphaprodine in ratios of 1:5, 
1:10, and 1:25 were equally effective in preventing respiratory depression; 
but the l:lO and 1:5 medications were followed b.r a high incidence of 
side effects, usually nausea, dizziness, and/or a sensation of falling. 
The two higher ratios appeared to be less effective than 1:25 in producing 
analgesia in those patients experiencing pain, and they did not unifo~ 
diminish responsiveness. 
When it became apparent that the 1:25 ratio of levallorphan to 
alphaprodine in combined administration did not produce the respiratory 
depression seen with the narcotic alone, the total dose of the narcotic 
was increased to 1.0, 1. 5, and 2.0 mg./kg. in combination with levallor-
phan at this ratio; three patients were chosen for each dose. No narcotic 
controls were done because it was felt that 1. 5 or 2. 0 mg. /kg. was above 
the safe clinical dose for alphaprodine, while it would be safe if 
levallorphan were added at a ratio of 1:25. The doses of alphaprodine 
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with antagonist were not depressant to respiration in any of the nine 
patients; but there was high incidence of side effects such as nausea, 
weird dreams, restlessness and confusion, as frequently seen with 
excessive doses of narcotics. 
(b) M!Peridine seriest 
This study demonstrated that appropriate admixture of levallor-
phan with meperidine prevented respiratory depression. Increasing the 
amount of levallorphan beyond a definite point produced no further changes 
in the respiration; however, side effects increased and responsiveness 
was reduced. No alterations in pulse or blood pressure were noted after 
the narcotic alone or in combination with levallorp~ The effect of 
meperidine alone and of the meperidine-levallorphan combinations are 
presented in Figures 8 and 9 and Tables 15 and 16. The statistical 
comparisons are presented in Tables 171 18, and 19. The effects of 
levallorphan alone and physiological saline were described earlier, but 
are also included in the tables so that appropriate comparisons can be 
made. 
After meperidine alone, 1. 5 mg. /kg. 1 the aTerage minute ventilation 
dropped to a low of 74 percent of normal in 20 minutes and returned to 
pre-injection levels in less than 60 minutes (Figure 8 and Table 16). The 
drop in ventilation was significantly below saline controls for the first 
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40 minutes only (Table 17). Respiratory rate also reached its nadir 20 
minutes after drug administration (82% of controls), and was significantlY" 
below physiological saline for the first 20 minutes only (Figure 9 and 
Tables 16 and 18). On the other hand, tidal volume which was quite variable 
FIGURE 8 
Changes in inspiratory minute ventilation following meperidine 
alone and in combination with levallorphan 
MEPERIDINE 1.5 mg./Kg. 
PLUS 
LEVALLORPHAN: 
e-e 0.1 000 mg./ KQ. ( I : 15 ) 
·---1 0.0500 II (I: 30) 
t······f 0.0250 " (I: 60) 
• • 0.0125 " (1: 120) 
o NONE 
10 20 30 40 50 60 
MINUTES AFTER INJECTION OF DRUG(S) 
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FIGURE 9 
Changes in respiratory rate following meperidine alone 
and in combination with levallorphan 
·-· . 
.. .. ····· - ~ ~. ········ 
' ····~t t ··t·· ·-' . . . ... . . . .. .. 
--
-- -- -- --
MEPERIDINE 1.5 mg./Kg. 
PLUS 
LEVALLORPHAN : 
e-eO.IOOOmg./Kg. (1:15) 
·---. 0.0500 II ( 1: 30) 
, ......... , 0.0250 II (I: 60) 
0 G 0.0125 II (1:120) 
o---o NONE 
10 20 30 40 50 60 
MINUTES AFTER INJECTION OF DRUG (S) 
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TABLE 15: Average General Responsiveness* After the Various 
Medications in the Meperidine Series 
Dose of levallorphan * Responsiveness at: 
Meperidine or salt solution, or 
56 
me;/ kg ratio levallorphan ·Time in minutes after drug administration 
to meperidine 
5 10 20 JJ be ~ ~ 
0 Pnysiologieal salt ,3.0 ,3.0 ,3.0 ,3.0 ).0 ,3.0 ,3.0 
solution 1. 5 or 
2.0 ml 
0 Levallorphan: 0.075 ,3.0 ,3.0 2.$** 2.5 2.5 2.5 2.5 
mg/kg 
1.5 0 2.5 2.0 2.0 2.0 2.0 2.0 2. 5 
1:120 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
1:60 2.0 1.5*'* 1.5 2.0 2.0 2.0 2.0 
1:)) 2. 5 2.0 2.0 2.0 2.0 2.5 2.5 
1:15 2.5 2.0 2.0 2.5 2.5 2.5 2.5 
* ** ' See notes Table 4 
TABLE 16: Means and Standard Errors of Observations on Respiratory 
Function in the Meperidine Series 
* ~eans and standard errors at: 
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Meperidine 
mg/kg 
Dose of levallorphan 
or salt solution, or 
ratio levallorphan 
to meperidine 
Time in minutes after drug administration 
, I lD I 20 I ~ 40 
A.. Inspiratory Minute Ventilation 
0 Physiological salt 
solution 1. 5 or 97~3 101!3 98t:3 9¢5 98!4 96t5 
-2.0 ml 
0 Levallorphan o.o75 94:!:3 98:!:6 97:!:2 98±2 lO.)tl l0lt2 
mg/kg --
1.5 0 77t8 77t5 74t5 74'.!:5 86t6 l0lt6 l06t4 
1:120 8)t9 85t5 84*4 86*6 91*3 100t2 100*1 
1:00 98t2 98%2 102'.!:2 97%2 100%2 root3 100±2 
1:~ 99i2 98±1 99±3 102±3 102±5 108±7 107!6 
1:15 9¢5 99%2 98±2 l01tl 98t2 97:!:2 102t1 
B. Respiratory Rate 
0 Physiological salt 
solution 1.5 or 102:!:4 l02t4 9st2 9.¢4 97t2 94:!:4 
--2.0 ml 
0 Levallo~han 0.075 92:!:4 96:!:2 92:!:8 95t5 98:!:5 97!4 
--
mg kg 
1.5 0 89±6 91:!:6 82!4 86t6 90±5 90±4 95t4 
1:120 84:!:6 84:!:6 88:!:5 86:!:6 89:!:5 95t4 98:!:5 
1:00 l04t8 106±8 101:!:8 101:!:7 105±7 10.)!6 104:!:6 
1:~ 91±5 95t5 98:!:6 98t6 99:!:5 98:!:4 98±6 
1:15 110±4 l06t4 103±3 105!3 105:!:3 104:!:3 106±2 
c. Inspiratory Tidal VollDile 
Physiological salt 
98!7 10ots 105:!:7 9¢4 102!7 101:!:4 solution 1. 5 or 
--
0 
2.0 m1 
Levallo~han o.o75 101*4 99*5 104*5 103*6 106*5 105*5 
-mg kg 
0 
1:5 0 87±8 86t7 9Jt8 89t7 98±10 ll4t8 114t6 
1:120 105±15 108t12 100±7 106±10 108t8 109t6 108t7 
1:00 107:!:10 10)tll 108tll 101:t8 101*9 102t8 99*5 
1:.30 lllt6 111:!:6 106±7 108t8 109t9 11.5tll 1121:8 
1:15 90:t4 9.5t3 95t3 97:!:3 94t3 94*2 97*2 
* Means are expressed as percent of control. 
TABLE 17: Statistical Comparison* of the Effects of Meperidine, Saline 
Solution and Meperidine-Levallorphan C011binations on Inspiratory 
Minute Ventilation 
Probability of difference, or significance: Dose of Ratio 
Time in minutes after drug administration Meperidine Levallorphan 
ag/kg to 
5 10 20 ~ 40 ~ 00 Meperidine 
1. Meperidine 1. 5 mg/kg compared to: Meperidine with 
Levallorphan 
N.S. ** N.s. <0.05 <0.05 N.s. N.S. <0.05 1.5 1:120 
<0.01 <0.01 <0.01 <0.01 <0.01 N.s. N.s. 1:60 
<0.01 <0.01 <0.01 <0.01 <0.01 N.s. N.S. lt~ 
<0.01 <0.01 <0.01 <0.01 <0.02 N.s. N.S. 1:15 
2. Saline solution 1. 5 or 2.0 lll compared to: Meperidine with 
Levallorphan 
<0.01 <0.01 <0.01 <0.01 <0.05 N.s. 
--
1.5 0 
<0.05 <0.01 <0.01 N.s. <0.05 <0.02 
-
1:120 
N.s. N.s. N.S. N.S. N.S. N.S. 
--
1:60 
N.S. N.S. N.S. N.s. N.S. N.S. 
--
1:~ 
N.s. N.s. N.s. <0.02 w.s. N.s. 
--
1:15 
.3. Meperidine and levallorphan 1:120 compared to: Meperidine with 
Levallorphan 
<0.05 <0.01 <0.01 <0.02 <0.01 N.s. N.S. 1.5 1:00 
<0.01 <0.01 <0.02 <0.01 <0.05 N.s. N.S. lt~ 
<0.05 <0.01 <0.01 <0.01 <0.02 N.s. N.S. 1:15 
4. Meperidine and levallorphan 1: to compared to: Meperidine w1 th 
Levallorphan 
N.s. N.s. N.S. N.S. N.S. N.S. N.s. 1.5 1:~ 
N.s. N.s. N.s. <0.05 N.s. N.S. N.s. 1:15 
5. Meperidine and levallorphan 1:~ compared to: Meperidine with 
Levallorphan 
N.S. N.s. N.S. N.S. N.S. <0.05 N.S. 1.5 1:15 
* by "t" test of student ** N. S. • Not significant 
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TABLE 18: Statistical Comparison* of the Effects of Meperidine, Saline 
Solution and Meperidine-Levallorphan Combinations on Respiratory Rate 
Probability of difference, or significance: Dose of Ratio 
Time in minutes after drug administration Meperidine Levallorphan 
110 I I 1 4o J I mg/kg to s ~ J) 5o {() Meperidine 
1. Meperidine 1. 5 mg/kg compared to: Meperidine with 
Levallorphan 
N.s. ** N.s. N.s. N.s. N.S. N.s. N.s. 1.5 1:120 
N.S. <O.os <0.05 <0.05 ~.os <O.os N.s. l:l() 
N.s. N.s. <0.01 <0.01 <0.02 <0.05 N.S. 1:.)) 
<0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 1:15 
2. Saline solution 1. 5 or 2.0 m1 compared tot Meperidine with 
Levallorphan 
<0.02 <O.os <0.01 N.s. N.s. N.s. 
--
1.5 0 
<0.01 <0.01 N.S. N.s. N.s. N.s. 
--
1:120 
N.s. N.s. N.S. N.S. N.s. N.S. 
--
1:60 
<0.01 N.s. N.s. N.s. N.s. x.s. 
--
1:.)) 
<0.05 N.s. <0.01 <0.01 <0.01 <0.01 
--
1:15 
). Meperidine and levallorphan 1:120 compared to: Meperidine with 
Levallorphan 
<0.02 <0.01 N.s. <0.05 <0.02 N.s. N.S. 1.5 1:60 
N.s. N.S. N.s. N.s. N.s. N.S. N.s. 1:30 
<0.01 <0.01 <0.01 <0.01 <0.01 <O.os <O.os 1:15 
4. Meperidine and levallorphan 1: 6o compared to: Meperidine with 
Levallorphan 
N.s. N.s. N.s. N.s. N.s. N.s. N.s. 1.5 1:.30 
N.s. N.s. N.S. N.S. N.s. N.s. N.S. 1:15 
5. Meperidine and levallorphan 1:)0 compared to: Meperidine with 
Levallorphan 
<0.01 <0.02 N.s. N.S. N.s. N.s. N.s. 1.5 1:15 
* ** ' See notes Table 17 
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* TABlE 19: Statistical Comparison of the Effects of Meperidine, Saline 
Solution and Meperidine-Levallorphan Combinations on Inspiratory 
Tidal Volume 
Probability of difference, or significance: Dose of Ratio Time in minutes after drug administration Meperidine Levallorphan 
I I I I I mg/kg to 5 10 20 )) 40 50 t:o Meperidine 
1. Meperidine 1. 5 mg/kg compared tot Meperidine with 
Levallorphan 
N.S. ** <0.05 N.s. N.s. N.S. N.s. N.S. 1.5 1:120 
<0.05 N.s. N.s. N.s. N.S. N.s. <0.02 l:t:o 
<0.01 <0.01 <0.05 <0.01 N.S. N.s. N.S. 1:.30 
N.s. N.s. N.s. N.s. N.s. <0.01 <0.01 1:15 
2. Saline solution 1. 5 or 2.0 Ill compared to: Meperidine with 
Levallorphan 
N.S. <O.o5 N.S. N.s. N.S. N.s. 
--
1.5 0 
N.s. N.S. N.s. N.s. N.s. N.S. 
--
1:120 
N.s. N.S. N.S. N.S. N.s. N.S. 
--
lt6o 
<0.05 N.S. N.s. N.S. N.S. N.S. 
--
1:.30 
N.s. N.S. <0.02 N.s. <O.o5 <0.01 
-
1:15 
.3. Meperidine and levallorphan 1:120 compared tot Meperidine with 
Levallorphan 
N.S. N.s. N.S. N.s. N.S. N.s. N.S. 1.5 l:t:o 
N.s. N.s. N.S. N.S. N.S. N.S. N.s. 1:.30 
N.s. N.s. N.s. N.s. <0.05 <0.01 <O.o5 1:15 
4. Meperidine and levallorphan 1: t:o compared to: Meperidine with 
Levallorphan 
N.s. N.s. N.S. N.s. N.S. N.S. N.S. 1.5 1:.30 
<0.05 N.S. N.S. N.s. N.S. N.S. N.s. 1:15 
S. Meperidine and levallorphan 1:.30 compared to: Meperidine with 
Levallorphan 
<0.01 <0.05 N.S. N.S. <O.o5 <0.02 <O.o5 1.5 1:15 
*, ** See notes Table 17 
failed to change significantly (Tables 16 and 19, pages 57 and 60. The 
average general responsiveness of these patients reached a value of 2.0 
in 10 minutes, and they remained lightly asleep for almost 60 minutes, 
at which time they began to recover from this state (Table 15, page 56). 
The observations on the effect of meperidine alone as well as the 
effect of physiological saline and levallorphan were used as a basis of 
comparison of the combined effect of the narcotic and antagonist. 
The combined effect of levallorphan with meperidine in ratios of 
1:120, 1:60, l:.J:>, and 1:15 is sholl!l in Figures 8 and 9, pages 54 and 55, 
and Tables 15 through 19, pages 56 - 60. When these ratios were compared 
to the narcotic alone, the inspiratory minute ventilation was significantly 
improved over the first 40 minutes for the 1:60, 1:30, and 1:15 ratios, 
while the 1:120 ratio produces significant differences only at the 20, 30, 
and 60 minute periods (Table 17, page 58). Tidal volume was variable 
and only the 1:30 ratio showed significant tmProvement for any length of 
time (first 30 minutes); the 1:15 ratio for the 50 and 60 minute periods 
and the 1:60 ratio at the 60 minute period were significantly below the 
narcotic control (Table 19, page 60). The respiratory rate for the 1:60, 
1:30, and 1:15 ratios only was significantly higher than meperidine alone 
(Table 18, page 59). 
When these ratios were compared to the saline controls, inspiratory 
ventilation was significantly different with respect to the 1:120 ratio 
only (Table 17, page 58), while tidal volume comparisons showed differences 
at more than one period after the 1:15 ratio only (Table 19, page 60). At 
the 1:120 ratio the respiratory rate is significantly below the saline 
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controls for the first 10 minutes, while the 1:15 ratio was significantly 
greater than the controls for most of the observations (Table 18, page 59). 
When the four ratios were compared to each other most of the differences 
were found when the 1:120 ratio was conpared to the other three. The 1:120 
ratio was significantly different from the others for the first 4o minutes 
for minute ventilation, while the other comparisons were not consistently 
different (Table 17, page 58). The only differences of any consequence 
that existed for tidal volume were 1:120 cf. 1:15, and 1:30 cf. 1:15. In 
these, 1:15 was significantly lower for the last three periods when compared 
to 1:120 and for all but the 20 and 30 minute periods when canpared to 
1:30 (Table 19, page 6o). Some differences existed between the 1:120 ratio 
and the 1:6o and 1:15 ratios for respiratory rate; the 1:30 and 1:15 ratios 
were different from each other for the first 10 minutes only (Table 18, 
page 59). 
We can summarize these results b,y saying that the 1:120 ratio improves 
the respiration partially and all other ratios tried completely prevent the 
respiratory depression that meperidine causes when given alone. This is 
particularly true when minute ventilation, the most important measurement 
to be made, is considered. Although l:t(), 1:30, and 1:15 prevent respira-
tory depression, side effects increase markedly for the 1:30 and particu• 
larly for the 1:15 ratio. 
Observations on responsiveness for all ratios are presented in Table 
15, page 56, and show that the values range from deep sleep to drowsiness 
( 1. 5 to 2. 5) , with the 1: 6o producing the greatest average reduction in 
responsiveness. 
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Preliminary trials with the 1:60 ratio were made to postoperative 
patients experiencing pain. This combination was chosen because it 
represented the smallest amount of levallorphan that was required to 
complete~ prevent respiratory depression. If more of the antagonist 
were added, there would be a greater chance of antagonizing the analgesia; 
and side effects would also be more frequent. Relief from pain was 
produced in most cases in which this combination was used; in a few, a 
second dose of the mixture was required. 
The observations on the combined effect of meperidine and daptazole 
demonstrated that the latter alone had no effect, and in combination 
with the narcotic did ~ prevent respiratory depression. As can be 
seen in Figure 10, depression of inspiratory minute ventilation occurred 
regardless of the amount of daptazole added. None of the ratios tested, 
1:15, 1:8, 1:4, or 1:2 were effective. Higher ratios than 1:2 could not 
be tried because of the danger of toxic effects of daptazole, usually 
central nervous system stimulation. The temporary return of minute 
ventilation to the normal at the 30 minute period for the 1:8 ratio was 
due to one patient whose ventilation exceeded the normal (142%) for this 
period only. 
(c) Morphine series: 
Efforts to produce a significant depression of respiration u,r 
morphine alone were largely unsuccessful. These results, plus the effect 
of levallorphan-morphine combination on respiration, are presented in 
Figure 11 and Table 20. The low dose of morphine, 0.15 mg./kg., produced 
a significant fall in minute ventilation below physiological saline for 
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FIGURE 10 
Minute inspiratory ventilation following meperidine alone, daptazole 
alone and the combination of the two in various rat.ios 
MEPERIDINE 1.5 mg./Kg. 
·-· --1, ...... , 
o--o 
X=X 
PLUS 
DAPTAZOLE: 
0.750 mg./Kg. 
0.375 II 
0.188 II 
0.100 " 
NONE 
(I : 2 ) 
(I : 4 ) 
( I : 8) 
( I : 15) 
OAPTAZOLE(alone) 0.5or0.8mg./Kg. 
10 20 30 40 50 60 
MINUTES AFTER INJECTION OF DRUG(S) 
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FIGURE 11 
Minute inspiratory ventilation following morphine alone at two 
doses and combined with levallorphan at the higher dose 
J-80 
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M orphine 
lllg/kg 
TABLE 20: Means and Standard Errors of Observations on Respiratory 
Function in the Morphine Series 
Dose of levallorphan Means * 
or salt solution Time in minl.l or ratio 
levallorphan to 
morphine , I 10 20J )) 40 5o to 1 75 90 
A. Inspiratory minute ventilations 
0.1$ 0 86t4 92t4 lOOt$ 104t3 103±3 102±2 104±4 10_5t6 10$±11 
0.20 0 88t3 90±5 92:!:4 88±4 88±4 89:!:3 92±4 99%6 96:!:4 
1:10 87!3 96!2: 93!1 9.3!2 96t2 96t2 102t4 98!2 95!3 
1:$ 94:!:3 951:3 90:!:4 96%2 89:!:6 93±3 9.3!4 98:!:3 97%.2 
B. Respiratory rate 
0.1$ 0 96!4 98!:8 97!7 100!8 98!:8 9$!6 100!11 103!10 .99!:12 
0.20 0 98!5 98!4 100!$ 95!5 99.!5 102:!:5 102:!:5 104:!:6 103:!:5 
1:10 100±$ 98:!:4 97:!:5 90±4 9J:!:6 9J:!:6 8$:!:4 86!5 86t5 
1:$ 92:!:4 98!3 94:!:2 100:!:4 9¢2 102:!:4 109:!:9 107:!:7 106:!:$ 
c. Inspiratory tidal volUDle 
0.1$ 0 90'!7 99:!:6 106'!9 107!7 109'!12 109!8 108'!12 108!13 121!32 
0.20 0 94:!:6 94:!:6 96!8 95!5 90:!:4 90:.!:5 93:!:5 101:!:7 95:!:5 
1:10 88±4 99±6 97t5 lOJ±5 106±6 10¢6 114:!:6 116t6 109%7 
1:5 10,3!4 98!2 98±4 98±4 90±7 93±6 89±9 92±6 93±4 
* Means are expressed as percent of preinjection values. 
lp$ .120 
102±12 112±8 
103:!:5 
100:!:2 
10$:!:3 
100!1 
100±1 98±2 
104!13 102!12 
110:!:7 111!7 
88±6 88±6 
108:!:7 107:!:7 
112±29 117±33 
98±7 100±7 
11$±7 114:!:7 
94±5 9:¢5 
~ 
the first S minutes only (p<O.OS), while morphine at 0.20 mg./kg. failed 
to produce a significant drop in ventilation. It is interesting to note 
though that there was a significant difference in inspiratoey ventilation 
between the high and low doses of the opiate at the .J>, 4o, and 5o minute 
periods (p<O.OS). Respiratory rate and tidal voluae were variable and not 
different from saline controls, nor were the two doses consistently 
different from each other. 
Since morphine can cause both depression and sti111ula tion, combina-
tions of the opiate with levallorphan could conceivably produce an increase 
of respiration that would exceed the no:rmal, provided the antagonist 
prevented depression only. Tests carried out using the high dose of 
morphine (0. 20 mg. /kg.) in ratios of opiate to antagonist of 1:10 and 
1: S failed to produce a change in respiration that vas significantly 
different from either p~siological saline or the low or high dose of 
the opiate (Figure 11, page 65, and Table 20, page 66). 
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DISCUSSION 
A major part of the research that has been reported in the litera-
ture on narcotic antagonists has been concerned with nalorphine. This 
compound is a morphine derivative in which the N-met~l group is replaced 
by an N-allyl group (see Figure 1, page 3). Other possible antagonists 
with a morphine-like structure were found to be less potent than 
nalorphine.41 In a comparable manner, theN-allyl deriTative of the 
narcotic levorph.an (levo-dromoran) is also a potent narcotic antagonist. 
This compound, leTallorphan, is a morphinan derivative (see Figure 1, 
page 3) that is more potent an antagonist than nalorphine. A comparison 
of these two antagonists vas made in rats by Costa and Bonnycastle. 45 
These authors found that levallorphan is at least twice as potent as 
nalorphine in preventing respiratoey depression produced by alphaprodine 
and morphine. No comparisons, however, have been made which included 
propallorphan, nor bas the latter antagonist been studied against 
narcotic induced respiratoey depression. 
In the present experiments on dogs it vas demonstrated that propall-
orphan is a potent narcotic antagonist. The marked reduction in respon-
siTeness which was produced by alphaprodine and morphine was completely 
reversed by this antagonist, an effect which is in keeping with the 
results found for levallorphan and nalorphine. The a bill ty of prop all-
orphan to reverse narcotic induced depression was quantitated in the 
subsequent dog experiments. Although the blood gases, expired gases and 
oxygen consumption were, in part, depressed by the narcotic and reversed 
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by the antagonist, these changes are presumably secondar,r to the changes 
in respiratory function; they do, however, give an indication of the 
magnitude of the depression. 
In still other animal experiments it was found that a ratio of lz75 
and 1:100 of propallorphan to alphaprodine prevented respiratory depression. 
These same ratios did not completely aaintain noraal respiratory exchange 
in man. They might have done so if larger doses of alphaprodine had been 
used. The reason for this is that with a greater depression produced, 
less antagonist is needed to neutralize the effect.47,53 It is also 
interesting to note that the lz 75 and 1:100 ratio lead to an increase in 
rate which exceeded the pre-injection level ( 11 ct. 20). Since the 
ventilation did not change .froa control values after the combination, the 
tidal volUile must have dropped as the rate increased. Such action of 
opiate antagonists is in keeping with the reports ot other workers. 5,47 ,80,8l 
In the studies on anesthetized dogs in which morphine-induced 
depression was antagonized by propallorphan, the duration of the effect of 
the latter on minute ventilation was 30 minutes, regardless of the dose. 
In one experiment nalorphine gave a similar result. It would therefore seem 
that under anesthesia the duration of antagonism of the respiratory 
depression is quite short. Most investigators have not considered the 
80 Eckenhotf, J. E., Helrich, M., Hege, K. J. D., and Jones, R. E., The 
combination of opiate antagonists and opiates for the prevention of 
respiratory depression, J. Pbarmacol. Exptl. Therap• 113:332, 1955. 
81 Radna;y, P. A. and Hechter, R. H., Effect of levallorphan tartrate on 
respiratory depression during nitrous oxide-oxygen anesthesia 
supplemented by levo-dromoran tartrate, J. Internatl. Col. Surg. ~:38, 
1955. 
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point in great detail. Payne82 found in hllllans that 10 mg. of nalorphine 
antagonized the respiratory depression produced b,y morphine for only 
' 18 
10 to 15 minutes. On the other hand, Eckenhoff et al. found that 10 
to 15 mg. of nalorphine injected intramuscularly .30 minutes before .30 :mg. 
of morphine (either intramuscularly or intravenously) prevented the 
depression of respiration by" the opiate. Miller et al. 47 found that the 
effect of levallorphan against morphine induced respiratory depression 
in the conscious rabbit lasted approxiu.tely 3 hours. Hart and McCawl~ 
· found that 5 mg. /kg. of nalorphine antagonized the depression produced 
by 10 mg./kg. of morphine with a major part of the reversal taking place 
during the first 30 minutes. Unfortunately none of these authors made a 
'• 
statistical evaluation of their results. More experiments are needed to 
evaluate this point in anesthetized and unanesthetized animals and in :man. 
In regard to the huaan studies, efforts to combine an antagonist 
with a narcotic to produce analgesia without undesirable side effects 
have not previously been wholly successful for two reasons: 1) the fact 
that differences in the amount either of the narcotic or of the antagonist 
may result in variations of over-all effect from stimulation to syner-
gistic depression83,84 has not been ~preciated; and, 2) adequate control 
82 Payne, J. P., Effects of N-allyl.normorphine on healthy subjects pre-
medicated with morphine, Brit. J. Anesthesia ~:22, 1954. 
83 Wendell, H. and Lambertsen, c. J., MecbaniSDl of action of N-allylnor-
morphine in morphine-induced respiratory depression in man, Fed. Proc. 
!2:497, 1956. 
84 Lasagna, L. and Beecher, H. K., The analgesic effectiveness of nalor-
phine· and nalorphine-morphine combinations in man, J. Pharmacol. Exptl. 
Therap. 1!1: 356, 1954. 
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studies of the effects of narcotic alone, antagonist alone and of some 
indifferent injection have not been included in the results of previous 
workers so that the published reports are not complete. The combined 
action of' levallorphan with alphaprodine at ratios of 1:100, 1:50 and 
1:25 has been reported by Swerdlow et a1. 85 while the combined action 
of levallorphan and levorphan (levo-dromoran) at ratios of' 1:10 to 1:1 
have been studied by Cullen and Santos28 and Eckenhoff et al. 80 The 
first two groups of investigators commented favorably on the analgesic 
and respiratory actions of this combined medication, while Eckenhoff 
and his coworkers found the antagonist of little or no value. Studies 
on meperidine in combination with antagonists has not been done largely 
because it has on:q recently been realized that this narcotic can cause 
a marked drop in ventilation in therapeutic doses.86,B7 While propall-
orphan (Ro-1-7780) is a new narcotic antagonist that has not received 
much attention as yet, daptazole has been investigated only superficiall.7. 
54,55,59-64 
With respect to lllOrphine, whether it causes a significant fall in 
ventilation in man is still questionable. For example, Dripps and 
85 Swerdlow, M., Foldes, F. F., and Siker, E. s., The effects of Nisentil 
hydrochloride (alphaprodine hydrochloride) and levallorphan tartrate 
on respiration, Am. J. Med. Sci. 230:237, 1955. 
-
86 Loeschcke, H. H., Sweel, .A.., Kough, R. H., and Lambertsen, c. J., 
The effect of morphine and of meperidine (Dolantin, Demerol) upon the 
respiratory response of normal men to low concentrations of inspired 
carbon dioxide, J. Pharmacal. Exptl. Therap. 108:376, 195.3. 
87 Orkin, L. R., Egge, R. K., and Rovenstine, E.· A., Effect of Nisentil@, 
meperidine and morphine on respiration in man, Anesthesiology 1:§.:699, 
1955. 
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Comroe88 in 1945 and Orkin et a1. 87 in 1955 found 10 or 15 mg. of 
morphine produced a transient drop in minute ventilation (80 to 87% 
of noraal) lasting approximatel7 5 minutes, but neither supplied placebo 
controls. Gravenstein et al. 89 in 1956 found a significant drop occurred 
with this opiate, which lasted 4 to 5 hours. All the above authors 
carried out their ventilation studies on human volunteers, not on post-
operative patients. Nornaal volunteers know that they are to receive 
an injection that will have either no effect or will cause depression. 
On the other hand, postoperative patients are not even aware that they 
are to receive an injection, much less what the drug will do to then. 
In spite of this point of issue, studies have been made on both human 
volunteers and patients in which more than one dose. of a narcotic 
antagonist has been combined with morphine. B4,90,9l,92 The results 
88 Dripps, R. D. and Comroe, J. H., Clinical studies on morphine. I. The 
immediate effect of morphine administered intravenously and intra-
muscularly upon the respiration of normal man, Anesthesiology 2:462, 
1945 
69 Gravenstein, J• s., Smith, G. M., Sphire, R. D., Isaacs, J. P., and 
Beecher, H. K., Further development in measurement of analgesic power 
and appraisal of psychologic side effects of analgesic agents, !!! 
Eng. J. Med. 254:877, 1956. 
90 Cappe, B. E. and Pallin, I. M., Recent advances in obstetric analgesia, 
J. A.m. Med. .Ass. ~: 377, 19.$4. 
91 Fraser, H. F., Van Horn, G. D., and Isbell, H., Studies on N-allylnor-
morphine in man: Antagonism to morphine and heroin and effects of 
mixtures of N-allylnomorphine and morphine, A.m. J. Med. Sci. 231:1, 
1956. 
92 Gaard., R. c., Preoperative use of a combination of levo-dromoran 
tartrate and a new narcotic antagonist, Minnesota Med. J. 38:637, 
u~ -
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presented b,y the various authors, however, were either inadequately 
controlled or the antagonist was found to be of little or no help, or 
both. 
In the present study, control observations of the actions of 
propallorphan, levallorphan, p~siological salt solution, alphaprodine, 
meperidine, and morphine have been made over comparable observation 
periods to those used in the tests of combined action; this has permitted 
the use of the statistics of small numbers to compare the various combi-
nations with the appropriate controls. 
With respect to alphaprodine and meperidine, significance of the 
difference between the controls and the tests has been demonstrated for 
inspiratory ventilation, respiratory rate to a lesser extent and tidal 
volUJie, which was quite variable, least of aU. Furthermore, the actual 
doses of narcotics and the ratios of antagonists to them have been 
varied from an amount presenting minimal narcosis and little perceptible 
antagonistic action to one where side effects of the combined medication 
have been prominent. The dose of alphaprodine itself, combined with 
levallorphan, has been increased into the toxic range without notable 
depression of vi tal functions in a small number of cases, using the 
intravenous route which presents the greatest hazard. 
Where analgesia was needed, the patients have gone lightly to sleep 
after the combined medication, indicating a satisfactory effect. In a 
number of patients outside the statistical study, where analgesia was 
a problem during or after abdominal surgery, administration intramuscularly 
of combined medication (levallorphan with alphaprodine at 1:30, and 
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levallorphan with meperidine at 1:6o) has produced excellent effects, 
as shown by cessation of restlessness, quieting of respiration with an 
actual increase in ventilation, and the induction of sleep. While the 
effects of the narcotics alone or of the combined medications on respira-
tory rate, and particularly on tidal volume, proved to be variable, their 
actions on the inspiratory minute Tentilation were consistent and signifi-
cant. 
The effects of injecting salt solution, propallorphan or levallor-
phan were negative, except that propallorphan, and levallorphan to a 
lesser extent, produced a slight depression in responsiTeness. 
The combined medications with alphaprodine, 0.75 mg./kg., at ratios 
of 1:100 and 1:50 produced a significant depression of ventilation below 
that seen in the controls during the first 5 and lO minutes respectiTel.;y. 
By contrast, the ventilation was not significantly' depressed at any time 
following the 1:37.5 and 1:25 combinations. Alphaprodine alone, at 
both doses, produced a significant depression of ventilation and a 
consistent change in responsiveness below the values which were seen 
after propallorphan alone, levallorphan alone, or salt solution. Again, 
the depression of ventilation with the 1:100 and l:Sb ratios of combined 
medication were not consistently' different from the narcotic alone during 
the critical period of observation, while the 1:37.5 and higher ratios 
were followed by higher ventilation (than after alphaprodine alone) 
throughout this period. Thus the combined medication, when compared to 
salt solution on the one hand and to alphaprodine alone on the other, 
produced consistent results. 
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Similar results were found in the meperidine-levallorphan studies. 
The 1: 120 is not significantly different from the narcotic alone during 
the critical period (first 10 minutes) for inspiratory ventilation, and 
is significantly different fran the saline controls. On the other hand, 
the 1:60, 1:30, and 1:15 ratios are significantly above the narcotic alone 
and are not different from physiological saline. 
Findings with respect to general responsiveness indicate propallorphan 
may be a more favorable drug for use with alphaprodine than levallorphan. 
While respiration was affected approximately equally when either of the 
drugs was added to the narcotic, responsiveness (a qualitative measure• 
ment not susceptible to statistical evaluation) was lower after the 1:25 
combinations containing propallorphan than after those containing 
levallorphan. Interestingly enough, in the meperidine studies, a ratio 
of 1:60 with levallorphan gave a greater reduction in general responsive-
ness than the other ratios or meperidine alone. 
The effectiveness of combining either propallorphan or levallorphan 
with alphaprodine, or levallorphan with meperidine in preventing narcotic 
respiratory depression is apparent. It further appears that the combined 
medications afford adequate analgesia. 
In contrast to the positive findings discovered with the other 
antagonists, daptazole was found to be ineffective in preventing respira-
tory depression produced by meperidine. The work done by other investiga-
tors who claimed this drug was effective failed to quantitate their 
results and did not have adequate controls. 62, 63 
In the morphine studies it was found that neither of the two doses 
15 
of the opiate tried produced a significant tall in ventilation when 
compared to the saline controls. There was, however, a significant 
difference between the two doses ot the opiate for a period of 30 
minutes; the higher dose, 0.2 mg./kg., producing the greater fall in 
ventilation. The addition of levallorphan at ratios of 1:10 and 1:5 also 
tailed to produce a significant change in respiration. It was mentioned 
earlier that reports have been made which indicated antagonists do not 
reverse the respiratory depression produced by morphine. The explanation 
for this could very well be that they did not have a significant drop 
in ventilation after morphine alone; therefore, the antagonists could 
not very well show a reversal. A.dded to this, an antagonist is more 
effective if a large degree of depression is present.47,BO 
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ABSTRACT 
In this study, propallorphan (/.- 3-hydroxy-N-propargylmorphina.n, 
Ro-1-7780) was found to be a potent antagonist to alphaprodine in 
both dog and man. The depression of general responsiveness (objective 
signs of central nervous system stimulation or depression) in conscious 
dogs by morphine and alphaprodine was reversed by propallorphan; while 
in anesthetized dogs, the changes in blood and expired gases as well as 
respiration brought about by alphaprodine were also antagonized by 
propallorphan. In another series of experiments, ratios of propallor-
phan to alphaprodine of 1:75 or 1:100 prevented the respiratory depression 
nonaally produced by the narcotic alone. It was also found that this 
antagonist reversed the respiratory depression produced by morphine; the 
effect lasted for a period of 30 minutes only before the opiate induced 
depression was reinstated. 
In the human studies, alphaprodine at doses of 0.375 to 2 mg./kg. 
were combined with the narcotic antagonists levallorphan Ct-3-hydroxy-
N-allylmorphinan) or propallorphan for postoperative medication. Ratios 
of the latter drugs to the former varied from 1:100 to 1:5. Ratios of 
1:100 and 1:50 produced a significant fall in respiration, while at 
ratios of 1:37.5 or higher, both antagonists were equally effective in 
preventing respiratory depression by the narcotic. Although the relief 
from pain produced by the combined medication at ratios of 1:100 to 
1:25 still appeared adequate, the ratios of ls37.5 and 1:25 were most 
favorable since respiration was not depressed. Although ratios of 1:10 
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and 1:5 prevented respiratory depression, side effects increased and 
relief from pain appeared inadequate. With admixture of levallorphan 
at a ratio of 1:25, alphaprodine 2 mg./kg., an ordinarily unsafe dose, 
produced no significant respiratory depression. 
Meperidine at a dose of 1:5 mg./kg. combined with levallorphan 
or daptazole was also studied in postoperative patients. Ratios of 
levallorphan to meperidine of 1:120 to 1:15 were tested. While 
meperidine alone produced a significant depression of ventilation, 
the 1:120 caused a smaller depression and the 1:6o, 1:30, and 1:15 
ratios completely prevented a reduction in respiration. The ratio of 
levallorphan to meperidine of 1:6o appeared most favorable, producing 
adequate relief from pain without respiratory depression or other 
undesirable side effects. By contrast, daptazole (2,4 diamino-5-phenyl-
thiazole) failed to alter the respiratory depression caused by meperidine. 
Morphine alone or in combination with levallorphan at ratios of 
1:10 or 1:5 did not show a significant change in ventilation when compared 
to saline controls. 
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